Misonix (MSON) 10-K17 Sep 142014 FY Annual reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
Document And Entity Information (USD $)	Jun. 30, 2014	Sep. 15, 2014	Dec. 31, 2013
Document Information [Line Items]	'	'	'
Entity Registrant Name	'MISONIX INC	'	'
Entity Central Index Key	'0000880432	'	'
Current Fiscal Year End Date	'--06-30	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Trading Symbol	'MSON	'	'
Entity Common Stock, Shares Outstanding	'	7,443,527	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	30-Jun-14	'	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2014	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Public Float	'	'	$35,274,726

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Jun. 30, 2013
Current assets:	'	'
Cash and cash equivalents	$7,039,938	$5,806,437
Accounts receivable, less allowance for doubtful accounts of $136,868 and $214,641, respectively	3,759,152	2,974,641
Inventories, net	4,217,350	4,034,477
Prepaid expenses and other current assets	367,830	387,371
Total current assets	15,384,270	13,202,926
Property, plant and equipment, net of accumulated amortization and depreciation of $ 4,842,009 and $4,105,292, respectively.	1,517,852	1,326,586
Goodwill	1,701,094	1,701,094
Intangible and other assets	924,653	1,129,321
Total assets	19,527,869	17,359,927
Current liabilities:	'	'
Accounts payable	1,650,323	2,208,999
Accrued expenses and other current liabilities	1,457,250	1,276,963
Total current liabilities	3,107,573	3,485,962
Deferred lease liability	16,614	23,811
Deferred income	51,318	72,934
Total liabilities	3,175,505	3,582,707
Commitments and contingencies (Note 8)	'	'
Stockholders' equity:	'	'
Common stock, $.01 par value-shares authorized 20,000,000, 7,412,096 and 7,233,884 shares issued and 7,334,536 and 7,156,324 shares outstanding, respectively	74,121	72,339
Additional paid-in capital	28,169,622	26,989,559
Accumulated deficit	-11,480,386	-12,873,685
Treasury stock, at cost, 77,560 shares	-410,993	-410,993
Total stockholders' equity	16,352,364	13,777,220
Total liabilities and stockholders' equity	$19,527,869	$17,359,927

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Allowance for doubtful accounts (in dollars)	$136,868	$214,641
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment (in dollars)	$4,842,009	$4,105,292
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	20,000,000	20,000,000
Common stock, shares issued	7,412,096	7,233,884
Common stock, shares outstanding	7,334,536	7,156,324
Treasury stock, shares	77,560	77,560

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
Consolidated Statements of Operations (USD $)	Jun. 30, 2014	Jun. 30, 2013
Net sales	$17,060,435	$14,827,226
Cost of goods sold	5,933,867	7,427,247
Gross profit	11,126,568	7,399,979
Operating expenses:	'	'
Selling expenses	7,272,726	6,776,204
General and administrative expenses	4,691,055	4,446,489
Research and development expenses	1,711,751	1,496,058
Total operating expenses	13,675,532	12,718,751
Loss from operations	-2,548,964	-5,318,772
Other income (expense):	'	'
Interest income	69	75
Interest expense	0	-7
Royalty income and license fees	3,725,436	2,511,655
Royalty expense	0	-13,361
Other	-19,331	-101,533
Total other income	3,706,174	2,396,829
Income/(loss) from continuing operations before income taxes	1,157,210	-2,921,943
Income tax expense/(benefit)	30,630	-75,196
Net income/(loss) from continuing operations	1,126,580	-2,846,747
Discontinued operations:	'	'
Income from discontinued operations net of tax expense of $235 and $1,853, respectively	19,666	3,596
Gain from sale of discontinued operations net of tax expense of $2,947 and $77,814, respectively	247,053	172,186
Net income from discontinued operations	266,719	175,782
Net income/(loss)	$1,393,299	($2,670,965)
Net income/(loss) per share from continuing operations - Basic (in dollars per share)	$0.15	($0.40)
Net income per share from discontinued operations - Basic (in dollars per share)	$0.04	$0.02
Net income/(loss) per share - Basic (in dollars per share)	$0.19	($0.38)
Net income/(loss) per share from continuing operations - Diluted (in dollars per share)	$0.15	($0.40)
Net income per share from discontinued operations - Diluted (in dollars per share)	$0.04	$0.02
Net income/(loss) per share - Diluted (in dollars per share)	$0.19	($0.38)
Weighted average shares - Basic (in shares)	7,232,004	7,050,423
Weighted average shares - Diluted (in shares)	7,467,592	7,050,423

Consolidated_Statements_of_Ope1

Consolidated Statements of Operations (Parenthetical) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Income from discontinued operations, Tax expense	$235	$1,853
Gain from sale of discontinued operations, Tax expense	$2,947	$77,814

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Balance at Jun. 30, 2012	$15,590,067	$70,829	($410,993)	$26,132,951	($10,202,720)
Balance (in shares) at Jun. 30, 2012	'	7,082,920	-77,560	'	'
Net income (loss)/comprehensive income	-2,670,965	0	0	0	-2,670,965
Proceeds from exercise of stock options	369,646	1,510	0	368,136	0
Proceeds from exercise of stock options (in shares)	'	150,964	0	'	'
Stock-based compensation	488,472	0	0	488,472	0
Balance at Jun. 30, 2013	13,777,220	72,339	-410,993	26,989,559	-12,873,685
Balance (in shares) at Jun. 30, 2013	'	7,233,884	-77,560	'	'
Net income (loss)/comprehensive income	1,393,299	0	0	0	1,393,299
Proceeds from exercise of stock options	484,960	1,782	0	483,178	0
Proceeds from exercise of stock options (in shares)	'	178,212	0	'	'
Stock-based compensation	696,885	0	0	696,885	0
Balance at Jun. 30, 2014	$16,352,364	$74,121	($410,993)	$28,169,622	($11,480,386)
Balance (in shares) at Jun. 30, 2014	'	7,412,096	-77,560	'	'

Consolidated_Statements_of_Sto1

Consolidated Statements of Stockholders' Equity (Parenthetical) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Common Stock, Par Value (in dollars per share)	$0.01	$0.01

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
Consolidated Statements of Cash Flows (USD $)	Jun. 30, 2014	Jun. 30, 2013
Operating activities	'	'
Net income/(loss) from continuing operations	$1,126,580	($2,846,747)
Adjustments to reconcile net income/(loss) to net cash provided by/(used in) by continuing operating activities:	'	'
Depreciation and amortization and other non-cash items	978,468	785,437
Bad debt (recovery)/expense	-77,773	58,902
Stock-based compensation	696,885	488,472
Deferred income	-17,786	-36,216
Deferred lease liability	-7,197	815
Changes in operating assets and liabilities:	'	'
Accounts receivable	-706,738	124,541
Inventories	-1,033,624	92,926
Prepaid expenses and other assets	106,741	40,488
Accounts payable, accrued expenses and other liabilities	-382,219	895,337
Net cash provided by/(used in) continuing operating activities	683,337	-396,045
Investing activities	'	'
Acquisition of property, plant and equipment	-72,437	-533,239
Additional patents	-129,078	-82,722
Net cash used in investing activities	-201,515	-615,961
Financing activities	'	'
Proceeds from exercise of stock options	484,960	369,646
Net cash provided by financing activities	484,960	369,646
Cash flows from discontinued operations	'	'
Net cash provided by/(used in) operating activities	16,719	-74,218
Net cash provided by investing activities	250,000	250,000
Net cash provided by discontinued operations	266,719	175,782
Net increase/(decrease) in cash and cash equivalents	1,233,501	-466,578
Cash and cash equivalents at beginning of year	5,806,437	6,273,015
Cash and cash equivalents at end of year	7,039,938	5,806,437
Supplemental disclosure of cash flow information:	'	'
Interest	0	7
Income taxes	$26,954	$32,341

Basis_of_Presentation_Organiza

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation and Significant Accounting Policies [Text Block]	'
	1. Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies

	Basis of Presentation

	The consolidated financial statements of MISONIX, INC. (“Misonix” or the “Company”) include the accounts of Misonix and its 100% owned subsidiaries, Fibra-Sonics (NY) Inc. and Hearing Innovations, Inc. All significant intercompany balances and transactions have been eliminated.

	Organization and Business

	Misonix is a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications.

	The Company’s revenues are generated from various regions throughout the world. Sales by the Company outside the United States are made primarily through distributors. Sales made in the United States are made primarily through representative agents. The following is an analysis of net sales from continuing operations by geographic region:

			For the years ended June 30,
			2014			2013
	United States		$	8,185,468		$	7,649,041
	Australia			120,118			358,509
	Europe			2,387,376			3,062,307
	Asia			3,572,056			1,619,255
	Canada and Mexico			779,833			516,088
	South America			1,165,124			735,060
	South Africa			378,287			489,756
	Middle East			472,173			397,210
			$	17,060,435		$	14,827,226

	Discontinued Operations

			For the years ended
			June 30,
			2014			2013
	Revenues		$	19,901		$	19,901
	Income from discontinued operations, before tax		$	19,901		$	5,449
	Gain on sale of discontinued operations			250,000			250,000
	Income tax expense			-3,182			-79,667
	Net income from discontinued operations, net of tax		$	266,719		$	175,782

	Laboratory and Forensic Safety Products Business

	On October 19, 2011, Misonix sold its Laboratory Products business, which comprised substantially all of the Laboratory and Scientific Products segment, to Mystaire, Inc. (“Mystaire”) for $1.5 million in cash plus a potential additional payment of up to an aggregate $500,000 based upon 30% of net sales in excess of $2.0 million for each of the three years following the closing (the “earn-out”). The Laboratory and Forensic Safety Products business manufactured and marketed ductless fume, laminar airflow and polymerase chain reaction workstations both domestically and internationally. The earn-out will not be factored into the gain on sale until it is earned by Misonix. As of June 30, 2014 there has been no earn-out recorded.

	High Intensity Focused Ultrasound Technology

	In consideration for the May 2010 sale of its rights to the high intensity focused ultrasound technology to USHIFU LLC (“USHIFU”), Misonix will receive up to approximately $5.8 million, paid out of an earn-out of 7% of gross revenues received by USHIFU related to the business being sold up to the time the Company has received the first $3 million and thereafter 5% of the gross revenues up to $5.8 million. Commencing 90 days after each December 31st and beginning December 31, 2011 the payments will be the greater of (a) $250,000 or (b) 7% of gross revenues received up to the time the Company has received the first $3 million and thereafter 5% of gross revenues up to the $5.8 million. Cumulative payments through June 30, 2014 were $754,788.

	Cash and Cash Equivalents

	The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.

	The Company maintains cash balances at various financial institutions. At June 30, 2014, these financial institutions held cash that was approximately $6,790,522 in excess of amounts insured by the Federal Deposit Insurance Corporation and other government agencies.

	Major Customers and Concentration of Credit Risk

	Included in sales from continuing operations are sales to Cicel (Beijing) Science and Tech Co. Ltd. of $2,495,960 and $619,357, Covidien plc (“Covidien”) of $5,226 and $110,437 and Aesculap, Inc. (“Aesculap”) of $636,085 and $1,425,708 for the fiscal years ended June 30, 2014 and 2013, respectively. Total royalties from Covidien related to their sales of the Company’s ultrasonic cutting products, which use high frequency sound waves to coagulate and divide tissue for both open and laparoscopic surgery, were $3,619,000 and $2,369,000 during the fiscal years ended June 30, 2014 and 2013, respectively. Accounts receivable from Covidien were approximately $892,000 and $718,000, which included $892,000 and $711,000 of royalty income receivable at June 30, 2014 and 2013, respectively. Accounts receivable from Aesculap were approximately $121,000 and $324,000 and from Cicel were approximately $606,000 and $179,000 at June 30, 2014 and 2013, respectively. At June 30, 2014 and 2013, the Company’s accounts receivable with customers outside the United States were approximately $1,332,000 and $1,086,000, respectively. The Company sells its BoneScalpel, SonaStar and Sonic One Wound Cleansing and Debridement System through direct sales persons and agents in the United States and through distributors outside the United States.

	Accounts Receivable

	Accounts receivable, principally trade, are generally due within 30 to 90 days and are stated at amounts due from customers, net of an allowance for doubtful accounts. The Company performs ongoing credit evaluations and adjusts credit limits based upon payment history and the customer's current credit worthiness, as determined by a review of their current credit information. The Company continuously monitors aging reports, collections and payments from customers and maintains a provision for estimated credit losses based upon historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within expectations and the provisions established, the Company cannot guarantee that the same credit loss rates will be experienced in the future. The Company writes off accounts receivable when they become uncollectible.

	Inventories

	Inventories are stated at the lower of cost (first-in, first-out) or market and consist of raw materials, work-in process and finished goods and include purchased materials, direct labor and manufacturing overhead. Management evaluates the need to record adjustments to write down inventory to the lower of cost or market on a quarterly basis. The Company’s policy is to assess the valuation of all inventories, including raw materials, work-in-process and finished goods and it writes down its inventory for estimated obsolescence based upon the age of inventory and assumptions about future demand and usage. During the year ended June 30, 2013 the Company also established inventory reserves aggregating approximately $835,000 resulting from terminating an agreement for products not meeting specifications for which recovery from the supplier is not expected. Inventory items used for demonstration purposes, rentals or on consignment are classified as property, plant and equipment.

	Property, Plant and Equipment

Property, plant and equipment are recorded at cost. Minor replacements and maintenance and repair expenses are charged to expense as incurred. Depreciation of property and equipment is provided using the straight-line method over estimated useful lives ranging from 3 to 5 years. Leasehold improvements are amortized over the life of the lease or the useful life of the related asset, whichever is shorter. The Company's policy is to periodically evaluate the appropriateness of the lives assigned to property, plant and equipment and make adjustments if necessary. Inventory items included in property, plant and equipment are depreciated using the straight line method over estimated useful lives of 3 to 5 years.

Revenue Recognition

The Company records revenue upon shipment for products shipped F.O.B. shipping point. Products shipped F.O.B. destination points are recorded as revenue when received at the point of destination. Shipments under agreements with distributors are not subject to return, and payment for these shipments is not contingent on sales by the distributor. Accordingly, the Company recognizes revenue on shipments to distributors in the same manner as with other customers. Fees from exclusive license agreements are recognized ratably over the terms of the respective agreements. Service contracts and royalty income are recognized when earned.

The Company presents taxes collected from customers and remitted to governmental authorities in the consolidated statements of operations on a net basis.

Long-Lived Assets

The carrying values of intangible and other long-lived assets, excluding goodwill, are periodically reviewed to determine if any impairment indicators are present. If it is determined that such indicators are present and the review indicates that the assets will not be fully recoverable, based on undiscounted estimated cash flows over the remaining amortization and depreciation period, their carrying values are reduced to estimated fair value. Impairment indicators include, among other conditions, cash flow deficits, an historic or anticipated decline in revenue or operating profit, adverse legal or regulatory developments, accumulation of costs significantly in excess of amounts originally expected to acquire the asset and a material decrease in the fair value of some or all of the assets. Assets are grouped at the lowest levels for which there are identifiable cash flows that are largely independent of the cash flows generated by other asset groups. No such impairment was deemed to exist in fiscal 2014 or 2013.

Goodwill

Goodwill is not amortized. We review goodwill for impairment annually and whenever events or changes indicate that the carrying value of an asset may not be recoverable. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of significant assets or products. Application of these impairment tests requires significant judgments, including estimation of cash flows, which is dependent on internal forecasts, estimation of the long term rate of growth for the Company’s business, the useful lives over which cash flows will occur and determination of the Company’s weighted average cost of capital. We primarily utilize a discontinued cashflow model in determining the fair value which consists of Level 3 inputs. Changes in the projected cash flows and discount rate estimates and assumptions underlying the valuation of goodwill could materially affect the determination of fair value at acquisition or during subsequent periods when tested for impairment. The Company completed its annual goodwill impairment tests for fiscal 2014 and 2013 as of June 30th each year. No impairment of goodwill was deemed to exist in fiscal 2014 or 2013.

Intangible and Other Assets

The cost of acquiring or processing patents is capitalized at cost. This amount is being amortized using the straight-line method over the estimated useful lives of the underlying assets, which is approximately 17 years. Net patents reported in intangible and other assets totaled $611,355 and $568,823 at June 30, 2014 and 2013, respectively. Accumulated amortization totaled $641,469 and $554,923 at June 30, 2014 and 2013, respectively. Amortization expense for the years ended June 30, 2014 and 2013 was approximately $83,000 and $75,000, respectively.

Net customer relationships, which are being amortized on a straight-line basis over a five year period, reported in intangible and other assets totaled $200,000 and $360,000 at June 30, 2014 and 2013, respectively. Accumulated amortization amounted to $600,000 and $440,000 at June 30, 2014 and 2013, respectively. Amortization expenses for the years ended June 30, 2014 and 2013 was $160,000 in each year.

The following is a schedule of estimated future amortization expense as of June 30, 2014:

					Customer
		Patents			Relationships
2015		$	85,931		$	160,000
2016			80,415			40,000
2017			78,231			-
2018			74,917			-
2019			68,333			-
Thereafter			223,528			-
		$	611,355		$	200,000

Income Taxes

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those periods in which temporary differences become deductible. Should management determine that it is more likely than not that some portion of the deferred tax asset will not be realized, a valuation allowance against the deferred tax asset would be established in the period such determination was made.

The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements from such position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. The Company classifies income tax related interest and penalties as a component of income tax expense.

Income (Loss) Per Share

Basic income (loss) per common share ("Basic EPS") is computed by dividing income (loss) by the weighted average number of common shares outstanding using the treasury stock method. Diluted income (loss) per common share ("Diluted EPS") is computed by dividing income (loss) by the weighted average number of common shares and the dilutive common share equivalents and convertible securities then outstanding.

The number of weighted average common shares used in the calculation of basic EPS and diluted EPS were as follows:

		For the twelve months ended						For the three months ended
		June 30,						June 30,
		2014			2013			2014		2013
Basic shares			7,232,004			7,050,423			7,301,157		7,115,557
Dilutive effect of stock options			235,588			-			383,685		-
Diluted shares			7,467,592			7,050,423			7,684,842		7,115,557

Excluded from the calculation of Diluted EPS are options to purchase 96,750 and 312,630 shares of common stock for the three and twelve months ended June 30, 2014, respectively. The excluded shares are any shares in which the average stock price for the quarter or year-to-date is less than the exercise price of the outstanding options in the period in which the Company has net income.

Diluted EPS for the three and twelve months ended June 30, 2013 presented is the same as Basic EPS, as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. For this reason, excluded from the calculations of Diluted EPS for the three and twelve months ended June 30, 2013 are outstanding options to purchase 1,729,991 shares.

Comprehensive Income/(Loss)

Total comprehensive income/(loss) was $1,393,299 for the fiscal year ended June 30, 2014 and ($2,670,965) for the fiscal year ended June 30, 2013.

Research and Development

All research and development expenses are expensed as incurred and are included in operating expenses.

Advertising Expense

The cost of advertising is expensed in the period the advertising first takes place. The Company incurred approximately $100,000 and $141,000 in advertising costs during the fiscal years ended June 30, 2014 and 2013, respectively.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and judgments that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are used for but not limited to, establishing the allowance for doubtful accounts, valuation of inventory, depreciation, asset impairment evaluations and establishing deferred tax assets and stock-based compensation. Actual results could differ from those estimates.

Shipping and Handling

Shipping and handling fees for the fiscal years ended June 30, 2014 and 2013 were approximately $75,000 and $47,000, respectively, and are reported as a component of net sales. Shipping and handling costs for the fiscal years ended June 30, 2014 and 2013 were approximately $85,000 and $101,000, respectively, and are reported as a component of selling expenses.

Stock-Based Compensation

The Company measures compensation cost for all share based payments at fair value and recognizes the cost over the vesting period. The Company utilizes the straight line amortization method to recognize the expense associated with the awards with graded vesting terms.

Recent Accounting Pronouncements

In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-08, “Presentation of Financial Statements (Topic 205)” and “Property, Plant and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity.” The amendments in the ASU change the criteria for reporting discontinued operations while enhancing related disclosures. The amendments in the ASU are effective in the first quarter of 2015. The Company is currently evaluating the impact of the pending adoption of ASU 2014 – 08 on its consolidated financial statements.

In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)." The new revenue recognition standard provides a five-step analysis to determine when and how revenue is recognized. The standard requires that a company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective for annual periods beginning after December 15, 2016 and will be applied retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is currently evaluating the impact of the pending adoption of ASU 2014-09 on its consolidated financial statements.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments

12 Months Ended

Jun. 30, 2014

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

2. Fair Value of Financial Instruments

We follow a three-level fair value hierarchy that prioritizes the inputs to measure fair value. This hierarchy requires entities to maximize the use of "observable inputs" and minimize the use of "unobservable inputs." The three levels of inputs used to measure fair value are as follows:

Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets as of the measurement date.

Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

Level 3: Significant unobservable inputs that reflect assumptions that market participants would use in pricing an asset or liability.

The following is a summary of the carrying amounts and estimated fair values of our financial instruments:

June 30, 2014

June 30, 2013

Carrying

Fair

Carrying

Fair

Amount

Value

Amount

Value

Cash and cash equivalents

7,039,938

5,806,437

Trade accounts receivable

3,759,152

2,974,641

Trade accounts payable

1,650,323

2,208,999

The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practicable to estimate that value:

Cash and Cash Equivalents

The carrying amount approximates fair value because of the short maturity of those instruments.

Trade Accounts Receivable

The carrying amount of trade receivables reflects net recovery value and approximates fair value because of their short outstanding terms.

Trade Accounts Payable

The carrying amount of trade payables approximates fair value because of their short outstanding terms.

Inventories

Inventories	12 Months Ended
Inventories	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	3. Inventories

	Inventories are summarized as follows:

		June 30,		June 30,
		2014		2013
	Raw material	$	1,820,046	$	2,641,982
	Work-in-process		410,827		394,629
	Finished goods		3,337,568		2,358,943
			5,568,441		5,395,554
	Less valuation reserve		1,351,091		1,361,077
		$	4,217,350	$	4,034,477

Property_Plant_and_Equipment

Property, Plant and Equipment	12 Months Ended
Property, Plant and Equipment	Jun. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	4. Property, Plant and Equipment

	Property, plant and equipment consist of the following:

		June 30,		June 30,
		2014		2013
	Machinery and equipment	$	1,887,309	$	1,861,167
	Furniture and fixtures		1,234,104		1,185,660
	Automobiles		22,328		22,328
	Leasehold improvements		445,879		443,233
	Demonstration and consignment inventory		2,770,241		1,919,490
			6,359,861		5,431,878
	Less: accumulated depreciation and amortization		-4,842,009		-4,105,292
		$	1,517,852	$	1,326,586

	Depreciation and amortization of property, plant and equipment totaled approximately $732,000 and $550,000 for the fiscal years ended June 30, 2014 and 2013, respectively.

Accrued_Expenses_and_Other_Cur

Accrued Expenses and Other Current Liabilities	12 Months Ended
Accrued Expenses and Other Current Liabilities	Jun. 30, 2014
Payables and Accruals [Abstract]	'
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	'
	5. Accrued Expenses and Other Current Liabilities

	The following summarizes accrued expenses and other current liabilities:

		June 30,		June 30,
		2014		2013
	Accrued payroll and vacation	$	460,341	$	456,095
	Accrued bonuses		250,000		225,000
	Accrued commissions		340,462		200,678
	Accrued professional and legal fees		85,832		70,450
	Deferred income		102,453		146,038
	Other		218,162		178,702
		$	1,457,250	$	1,276,963

Leases

Leases	12 Months Ended
	Jun. 30, 2014
Leases [Abstract]	'
Leases of Lessor Disclosure [Text Block]	'
	6. Leases

	Misonix has entered into several noncancellable operating leases for the rental of certain manufacturing and office space, equipment and automobiles expiring in various years through 2018. The principal building lease provides for a monthly rental of approximately $23,000. The Company also leases certain office equipment and automobiles under operating leases expiring through fiscal 2018.

	The following is a schedule of future minimum lease payments, by year and in the aggregate, under operating leases with initial or remaining terms of one year or more at June 30, 2014:

		Operating
		Leases
	2015	$	332,017
	2016		33,606
	2017		28,032
	2018		7,540
	Total minimum lease payments	$	401,195

	Certain of the leases provide for escalation clauses, renewal options and the payment of real estate taxes and other occupancy costs. Rent expense for all operating leases was approximately $392,000 and $387,000 for the fiscal years ended June 30, 2014 and 2013, respectively.

StockBased_Compensation_Plans

Stock-Based Compensation Plans	12 Months Ended
Stock-Based Compensation Plans	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	7. Stock-Based Compensation Plans

	Stock options are granted with exercise prices not less than the fair market value of our common stock, par value $.01 per share (“Common Stock”), at the time of the grant, with an exercise term as determined by the Committee administering the applicable option plan (the "Committee") not to exceed 10 years. The Committee determines the vesting period for the Company's stock options. Generally, such stock options have vesting periods of immediate to four years. Certain option awards provide for accelerated vesting upon meeting specific retirement, death or disability criteria, and upon change of control. During the fiscal years ended June 30, 2014 and 2013, the Company granted options to purchase 324,000 and 357,500 shares of the Company's Common Stock, respectively.

	Compensation expense is recognized in the general and administrative expenses line item of the Company's consolidated statements of operations on a straight-line basis over the vesting periods. There are no capitalized stock-based compensation costs at June 30, 2014 and 2013. As of June 30, 2014, there was approximately $1,693,000 of total unrecognized compensation cost related to non-vested share-based compensation arrangements to be recognized over a weighted-average period of 2.8 years.

	Cash received from the exercise of stock options for the fiscal years ended June 30, 2014 and 2013 was $484,960 and $369,646, respectively. Cash flows from tax benefits attributable to tax deductions in excess of the compensation cost recognized for those options (excess tax benefits) are classified as financing cash flows. The intrinsic value of stock options exercised during the fiscal year ended June 30, 2014 aggregated approximately $341,000.

	The weighted average fair value at date of grant for options granted during the fiscal years ended June 30, 2014 and 2013 was $3.95 and $3.04 per share, respectively. The fair value of options at date of grant was estimated using the Black-Scholes option-pricing model utilizing the following assumptions:

			2014			2013
	Risk-free interest rates			3	%		2.5	%
	Expected option life in years			6.5			6.5
	Expected stock price volatility			76.09	%		75.15	%
	Expected dividend yield			0	%		0	%

	The risk free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The expected option term is based upon the number of years the Company estimates the option will be outstanding based on historical exercises and terminations. The expected dividend yield is based upon historical and projected dividends. The Company estimates volatility based upon historical price changes of the Company’s stock over a period equal to that of the expected life of the option.

	In March 1996, the Board of Directors adopted and, in February 1997, the shareholders approved the 1996 Employee Incentive Stock Option Plan covering an aggregate of 450,000 shares (the "1996 Plan") and the 1996 Non-Employee Director Stock Option Plan (the "1996 Directors Plan") covering an aggregate of 1,125,000 shares of Common Stock. At June 30, 2014, options to purchase 41,000 shares were outstanding under the 1996 Plan at exercise prices ranging from $5.18 to $7.60 per share all of which are currently vested and options to acquire 75,000 shares were outstanding under the 1996 Directors Plan at exercise prices ranging from $5.87 to $7.60 per share all of which are currently vested. At June 30, 2014, options to purchase 138,295 shares under the 1996 Plan have been exercised and options to purchase 422,650 shares have been forfeited (of which options to purchase 270,705 shares have been reissued). As of June 30, 2014, there were no shares available for future grants. At June 30, 2014, options to purchase 853,500 shares under the 1996 Directors Plan have been exercised and options to purchase 130,000 shares have been forfeited (of which none have been reissued). As of June 30, 2014, there were no shares available for future grants.

	In October 1998, the Board of Directors adopted and, in January 1999, the shareholders approved the 1998 Employee Stock Option Plan (the "1998 Plan") covering an aggregate of 500,000 shares of Common Stock. At June 30, 2014, options to purchase 10,750 shares were outstanding under the 1998 Plan at an exercise price of $7.60 per share all of which are currently vested. At June 30, 2014, options to purchase 76,848 shares under the 1998 Plan have been exercised and options to purchase 477,677 shares under the 1998 Plan have been forfeited (of which options to purchase 65,275 shares have been reissued). At June 30, 2014, there were no shares available for future grants.

	In October 2000, the Board of Directors adopted and, in February 2001, the shareholders approved the 2001 Employee Stock Option Plan (the "2001 Plan") covering an aggregate of 1,000,000 shares of Common Stock. At June 30, 2014, options to purchase 220,968 shares were outstanding under the 2001 Plan at exercise prices ranging from $1.82 to $8.00 per share with a vesting period of one to four years. At June 30, 2014, options to purchase 192,318 shares under the 2001 Plan have been exercised and options to purchase 837,975 shares under the 2001 Plan have been forfeited (of which 251,261 options have been reissued). At June 30, 2014, there were no shares available for future grants.

	In September 2005, the Board of Directors adopted and, in December 2005, the shareholders approved, the 2005 Employee Equity Incentive Plan (the "2005 Plan") covering an aggregate of 500,000 shares of Common Stock and the 2005 Non-Employee Director Stock Option Plan (the "2005 Directors Plan") covering an aggregate of 200,000 shares of Common Stock. At June 30, 2014, options to purchase 329,925 shares were outstanding under the 2005 Plan at exercise prices ranging from $.85 to $6.18 per share with a vesting period of four years. At June 30, 2014 options to purchase 169,450 shares have been exercised under the 2005 Plan and options to purchase 47,750 shares have been forfeited (of which 47,125 options have been reissued). At June 30, 2014, 625 shares were available for future grants under the 2005 Plan. At June 30, 2014, options to purchase 165,000 shares were outstanding under the 2005 Directors Plan at exercise prices ranging from $2.41 to $5.42 with a vesting period over three years. At June 30, 2014, options to purchase 22,500 shares under the 2005 Directors Plan have been exercised and options to purchase 7,500 shares have been forfeited (of which none have been reissued). At June 30, 2014, there were 12,500 shares available for future grants under the 2005 Directors Plan.

	In December 2009, the Board of Directors and shareholders adopted the 2009 Employee Equity Incentive Plan (the "2009 Plan") covering an aggregate of 500,000 shares of Common Stock and the 2009 Non-Employee Director Stock Option Plan (the "2009 Directors Plan") covering an aggregate of 200,000 shares of Common Stock. At June 30, 2014, options to purchase 470,936 shares were outstanding under the 2009 Plan at exercise prices ranging from $1.82 to $6.18 per share with a vesting period of four years. At June 30, 2014, options to purchase 20,464 have been exercised and options to purchase 76,525 shares were forfeited under the 2009 Plan (of which 67,925 options have been reissued). At June 30, 2014, there were 8,600 shares available for future grants under the 2009 Plan. At June 30, 2014, options to purchase 176,250 shares were outstanding under the 2009 Directors Plan at exercise prices ranging from $2.41 to $6.71 with a vesting period of up to four years. At June 30, 2014, there were 7,500 options exercised and options to purchase 11,250 shares were forfeited under the 2009 Directors Plan (of which none have been reissued). At June 30, 2014, there were 16,250 shares available for future grants under the 2009 Directors Plan.

	In December 2012, the Board of Directors and shareholders adopted the 2012 Employee Equity Incentive Plan (the “2012 Plan”) covering an aggregate of 500,000 shares of Common Stock and the 2012 Non-Employee Director Stock Option Plan (the “2012 Directors Plan”) covering an aggregate of 200,000 shares of Common Stock. At June 30, 2014, options to purchase 173,500 shares were outstanding under the 2012 Plan at an exercise price of $4.68 per share with a vesting period of four years. At June 30, 2014, there were no options exercised and options to purchase 6,000 shares were forfeited under the 2012 Plan (of which none have been reissued). At June 30, 2014, 326,500 shares were available for future grants under the 2012 Plan. At June 30, 2014, there were no options outstanding, exercised, or forfeited under the 2012 Directors Plan. At June 30, 2014, 200,000 shares were available for future grants under the 2012 Directors Plan.

	The selection of participants, allotments of shares and determination of price and other conditions relating to options are determined by the Board of Directors or a committee thereof, depending on the Plan, and in accordance with Rule 4350(c) of the Corporate Governance Requirements applicable to Nasdaq-listed companies. Incentive stock options granted under the plans are exercisable for a period of up to ten years from the date of grant at an exercise price which is not less than the fair market value of the Common Stock on the date of the grant, except that the term of an incentive stock option granted under the plans to a shareholder owning more than 10% of the outstanding Common Stock may not exceed five years and its exercise price may not be less than 110% of the fair market value of the Common Stock on the date of grant. Options shall become exercisable at such time and in such installments as provided in the terms of each individual option agreement.

	The following table summarizes information about stock option activity during 2014 and 2013:

			Options
									Weighted
									Average
						Weighted			Remaining
			Number			Average			Contractual			Aggregate
			of			Exercise			Life			Intrinsic
			Shares			Price			Years			Value
	Outstanding as of June 30, 2013			1,729,991		$	3.65
	Granted			324,000			4.94
	Exercised			-178,212			2.72					$	341,479
	Forfeited			-50,250			4.31
	Expired			-162,200			4.67
	Outstanding as of June 30, 2014			1,663,329		$	3.88			5.2		$	4,879,106
	Vested and exercisable at June 30, 2014			967,056		$	3.81			4.3		$	2,937,802

	Outstanding as of June 30, 2012			1,820,930		$	3.6
	Granted			357,500			3.83
	Exercised			-150,964			2.45					$	86,972
	Forfeited			-95,775			2.41
	Expired			-201,700			5.1
	Outstanding as of June 30, 2013			1,729,991		$	3.65			5.4		$	2,937,132
	Vested and exercisable at June 30, 2013			1,104,817		$	3.97			3.6		$	1,554,007

	The following table summarizes information about stock options outstanding at June 30, 2014:

			Options Outstanding									Options Exercisable
						Weighted
						Average			Weighted						Weighted
	Range of					Contractual			Average						Average
Exercise					Life			Exercise						Exercise
Prices		Number			(Yrs.)			Price			Number			Price
$0.85-2.96			850,899			6.2		$	2.38			533,601		$	2.27
$3.45-4.68			299,800			6.2		$	4.51			56,800		$	3.76
$5.18-8.00			512,630			3		$	6.01			376,655		$	6
			1,663,329			5.2		$	3.88			967,056		$	3.81

As of June 30, 2014 and 2013, 1,663,329 and 1,729,991 shares are reserved for issuance under outstanding options and 564,475 and 854,725 shares are reserved for the granting of additional options, respectively. All outstanding options expire between September 2014 and December 2023 and vest over periods of up to four years.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	8. Commitments and Contingencies

	Employment Agreement

	On July 1, 2014 the Company entered into a new Employment Agreement with Michael A. McManus, Jr., whereby he will continue to serve as the Company’s President and Chief Executive Officer (the “Agreement”). The Agreement has an initial term expiring June 30, 2015 and renews for successive one-year periods thereafter unless terminated by either party not less than ninety (90) days prior to the end of the then-current term. The Agreement provides for an annual base salary of $299,000, and an annual bonus based on Mr. McManus’ achievement of annual goals and objectives as determined by the Compensation Committee of the Company’s Board of Directors.

	Mr. McManus is entitled under the Agreement to participate in any plans and programs made available to the executive employees of the Company generally.

	The Company can terminate the Agreement for cause (as defined in the Agreement). Mr. McManus can terminate the Agreement for Good Reason (as defined in the Agreement). If Mr. McManus terminates the Agreement for Good Reason, the Company must pay him an amount equal to two times his total compensation (annual base salary plus bonus) at the highest rate paid him at any time during the aggregate time he has been employed by the Company, payable in a lump sum within sixty (60) days of termination of employment.

	Mr. McManus is entitled to severance pay and benefits if he terminates his employment with the Company following a Change in Control (as defined in the Agreement), to provide him with an incentive to remain with the Company and consummate a strategic corporate sale or transaction that maximizes shareholder value. Severance pay and benefits are triggered upon (i) his Involuntary Termination without Cause (as defined in the Agreement) for a reason other than death or Disability (as defined in the Agreement) or (ii) as a result of a Constructive Termination (as defined in the Agreement) which in either case occurs: (x) during the period not to exceed twenty-four (24) months after the effective date of a Change in Control, or (y) before the effective date of a Change in Control, but after the first date on which the Board of Directors and/or senior management of the Company has entered into formal negotiations with a potential acquirer that results in the consummation of a Change in Control.

	In the event that pay and benefits are triggered, Mr. McManus (A) is entitled to receive severance pay in an amount equal to two (2) times the sum of (a) his annual base pay and (b) bonus at the highest rate paid him for any fiscal year during the aggregate period of his employment by the Company, payable in cash in a lump sum; the payment of premiums for medical, dental, vision, hospitalization and long term care coverage under Company plans for a period of twenty-four (24) months; (B) has the right, for a period of (i) ninety (90) days for stock options granted under any of the Company’s Employee Stock Option Plans adopted prior to 2005 and (ii) two (2) years for stock options granted under the Company’s 2005 Employee Equity Incentive Plan, 2009 Employee Equity Incentive Plan, 2012 Employee Equity Incentive Plan and any Plan adopted after the effective date of the Agreement following his Termination Date (as defined in the Agreement), to exercise the options to the extent such options are otherwise vested and exercisable as of the Termination Date under the terms of the applicable stock option agreement(s) and plan(s); and (C) will vest in all unvested stock option grants with respect to options granted after July 1, 2012.

	Mr. McManus has also agreed in the Agreement to an eighteen (18) month post-termination covenant not-to-compete, as well as other customary covenants concerning non-solicitation and non-disclosure of confidential information of the Company.

	The Company and Mr. McManus had previously entered into two letter agreements (the “Letter Agreements”) providing for the exercise of vested options by Mr. McManus (i) for a ninety (90) day period after his retirement with respect to stock options granted under certain of the Company’s stock option plans and (ii) for two (2) years after Mr. McManus terminates his employment with the Company in the event of a Change-in-Control (as defined in the applicable stock option plans) and he is eligible for the severance benefits provided for by the Agreement. The Company and Mr. McManus have entered into a letter agreement which makes clear that the terms and conditions of the Letter Agreements continue to be in full force and effect and apply to the Agreement.

	Purchase Commitments

	As of June 30, 2014 and 2013, the Company had purchase and inventory commitments totaling $2,300,949 and $1,510,566, respectively.

	Contingencies

	The Company and its subsidiaries are from time to time involved in ordinary and routine litigation. Management presently believes that the ultimate outcome of these proceedings, individually or in the aggregate, will not have a material adverse effect on the Company’s financial position, cash flows or result of operations. Nevertheless, litigation is subject to inherent uncertainties and an unfavorable ruling could occur. An unfavorable ruling could include money damages and in such event, could result in a material adverse impact on the Company’s results of operations in the year in which the ruling occurs.

	On July 19, 2011, Misonix entered into a Distribution Agreement (the “Distribution Agreement”) with Puricore, Inc. (“Puricore”). Pursuant to the Distribution Agreement, the Company had been granted the right to distribute PuriCore’s Vashe^® solution products in the United States, on a private label basis and known as the Misonix Soma product, as an antibacterial, antimicrobial irrigating solution for the treatment of human wound care in conjunction with therapeutic ultrasonic procedures (the “Field”). PuriCore had agreed, subject to modification, not to sell the products that were the subject of the Distribution Agreement (the “Licensed Products”) to any other therapeutic ultrasound company for distribution in the Field in the United States (“Exclusivity”). The Company had agreed not to sell or distribute in the United States in the Field any irrigating solution that has anti-microbial properties other than the Licensed Products so long as the Company had Exclusivity.

	During our fiscal fourth quarter 2013, the Company sent a notice to terminate the Distribution Agreement due to management’s belief that the products subject to the Distribution Agreement were non-conforming. Puricore disputed the Company’s ability to terminate the Distribution Agreement. On October 11, 2013, the Company and Puricore mutually terminated the Distribution Agreement and signed a Settlement Agreement resolving all issues without the payment of any monies by either party. A reversal of the previously accrued and unpaid contractual minimum gross profit requirement in the amount of $439,508 was made through cost of goods sold in the quarter ended December 31, 2013 as a result of the Settlement Agreement. There are no further commitments to Puricore.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
Related Party Transactions	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	9. Related Party Transactions

	Stavros G. Vizigianakis was appointed to the Board of Directors on May 7, 2013. Mr. Vizigianakis owned a controlling interest in MD Solutions Australasia PTY Ltd. during the fiscal year ended June 301, 2014. Mr. Vizigianakis subsequently sold his entire position prior to June 30, 2014. Mr. Vizigianakis and a family member own one hundred percent of Applied BioSurgical which is part of Ascendis Healthcare, a listed entity on the Johannesburg Stock Exchange. The distributor agreements with such companies pre-date Mr. Vizigianakis’ appointment to the Board of Directors.

	Set forth below is a table showing the Company’s net sales and accounts receivable for the fiscal years ended June 30, 2014 and June 30, 2013 with these distributors:

	For the years ended June 30,

	Applied Bio Surgical	2014		2013

	Sales	$	378,287	$	489,592
	Accounts receivable		147,585		130,123

	MD Solutions	2014		2013
	Australasia PTY Ltd.	2014		2013

	Sales	$	120,118	$	335,274
	Accounts receivable		1,785		18,700

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	10. Income Taxes

	Open tax years related to federal and state income tax filings are for the years ended June 30, 2011, 2012, 2013 and 2014. The Company’s net operating loss carryforwards from closed years can be adjusted by the tax authorities when they are utilized in an open year. The Company files state tax returns in New York and Texas. The Company's foreign subsidiaries, Misonix Ltd. and Misonix Urology Services Limited (formerly, UKHIFU Limited), filed tax returns in the United Kingdom. In general, open years related to the United Kingdom for filing are June 30, 2012, 2013 and 2014. As of June 30, 2014 and 2013, the Company has no material unrecognized tax benefits and no accrued interest and penalties.

	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.

	The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities are presented below:

			June 30,
			2014			2013
	Deferred tax liabilities:
	Depreciation and amortization		$	-358,421		$	-299,896
	Total deferred tax liabilities			-358,421			-299,896

	Deferred tax assets:
	Bad debt reserves			47,227			56,842
	Accruals and allowances			13,512			13,504
	Inventory valuation			612,420			611,272
	License fee and other income			31,428			59,602
	Stock-based compensation			225,925			225,793
	Deferred gain - HIFU and Labcaire			196,773			203,946
	Tax credits			702,776			534,163
	Net operating loss carry forwards			4,636,476			5,235,264
	Other			24,031			22,512
	Total deferred tax assets			6,490,568			6,962,898
	Valuation allowance			6,132,147			6,663,002
	Net deferred tax asset		$	-		$	-

	Recorded as:
	Current deferred tax asset		$	-		$	-
	Non-current deferred tax liability, net			-			-
			$	-		$	-

	As of June 30, 2014, the valuation allowance was determined by estimating the recoverability of the deferred tax assets. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. In making this assessment, the ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and tax planning strategies. Based on these considerations, management concluded that it is more likely than not that its deferred tax assets will not be fully realized. The decrease in the valuation allowance is primarily due to the net income from continuing and discontinued operations.

	As of June 30, 2014, the Company had approximately $11,700,000 of U.S. federal net operating loss carryforwards which expire in tax years between 2026 and 2033. Of the net operating loss carryforwards, approximately $3,900,000 is subject to the separate return loss rules under the Internal Revenue Code of 1986, as amended (the “Code”). The Company has approximately $596,000 of research and development tax credit carryforwards which expire in the tax years between 2026 and 2034. In addition, the Company has approximately $107,000 of alternative minimum tax credit which has an indefinite carryforward period.

	Significant components of the income tax expense (benefit) attributable to continuing operations are as follows:

			Year ended June 30,
			2014			2013
	Current:
	Federal		$	24,613		$	-79,667
	State			6,017			4,471
	Total current			30,630			-75,196

	Deferred:
	Federal			-			-
	State			-			-
	Total deferred			-			-
			$	30,630		$	-75,196

	The reconciliation of income tax expense (benefit) computed at the Federal statutory tax rates to income tax expense (benefit) is as follows:

			Year ended June 30,
			2014			2013
	Tax at federal statutory rates		$	393,451		$	-993,461
	State income taxes, net of federal benefit			3,971			2,951
	Research credit			-140,044			-58,777
	Stock-based compensation			236,941			166,080
	Valuation allowance			-486,106			782,808
	Travel and entertainment			21,587			24,860
	Other			830			343
		$	30,630		$	-75,196

Licensing_Agreements_for_Medic

Licensing Agreements for Medical Technology	12 Months Ended
Licensing Agreements for Medical Technology	Jun. 30, 2014
Licensing Agreements For Medical Technology [Abstract]	'
Licensing Agreements For Medical Technology [Text Block]	'
	11. Licensing Agreements for Medical Technology

	In October 1996, the Company entered into a License Agreement (the "USS License") with United States Surgical (now, Covidien) for a twenty-year period, expiring October 2016, covering the further development and commercial exploitation of the Company's medical technology relating to laparoscopic products, which uses high frequency sound waves to coagulate and divide tissue for both open and laparoscopic surgery.

	The USS License gives Covidien exclusive worldwide marketing and sales rights for this technology. Under the USS License, the Company has received $475,000 in licensing fees (which are being recorded as income over the term of the USS License), plus royalties based upon net sales of AutoSonix products. Total royalties from sales of this device were approximately $3,619,000 and $2,369,000 for the fiscal years ended June 30, 2014 and 2013, respectively.

Employee_Profit_Sharing_Plan

Employee Profit Sharing Plan	12 Months Ended
Employee Profit Sharing Plan	Jun. 30, 2014
Compensation and Retirement Disclosure [Abstract]	'
Compensation and Employee Benefit Plans [Text Block]	'
	12. Employee Profit Sharing Plan

	The Company sponsors a retirement plan pursuant to Section 401(k) of the Code for all full time employees. Participants may contribute a percentage of compensation not to exceed the maximum allowed under the Code, which was $17,500 or $23,000 if the employee was over 50 years of age for the year ended June 30, 2014. The plan provides for a matching contribution by the Company of 10% of annual eligible compensation contributed by the participants based on years of service, which amounted to $38,320 and $38,510 for the fiscal years ended June 30, 2014 and 2013, respectively.

Quarterly_Results_unaudited

Quarterly Results (unaudited)	12 Months Ended
Quarterly Results (unaudited)	Jun. 30, 2014
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Information [Text Block]	'
	13. Quarterly Results (unaudited)

			FISCAL 2014
			Q1			Q2				Q3			Q4			YEAR
	Net sales		$	3,075,584		$	4,122,059			$	4,284,645		$	5,578,147		$	17,060,435
	Cost of goods sold			1,345,330			1,229,409	A			1,431,766			1,927,362			5,933,867
	Gross profit			1,730,254			2,892,650				2,852,879			3,650,785			11,126,568

	Operating expenses:
	Selling expenses			1,828,830			1,683,699				1,913,795			1,846,402			7,272,726
	General and administrative expenses			1,221,315			1,120,926				1,176,047			1,172,767			4,691,055
	Research and development expenses			472,888			435,019				406,466			397,378			1,711,751
	Total operating expenses			3,523,033			3,239,644				3,496,308			3,416,547			13,675,532
	(Loss)/income from operations			-1,792,779			-346,994				-643,429			234,238			-2,548,964

	Other income/(expense):
	Interest income			19			19				18			13			69
	Royalty income and license fees			912,794			809,392				830,702			1,172,548			3,725,436
	Other			-6,261			-5,304				-5,121			-2,645			-19,331
	Total other income			906,552			804,107				825,599			1,169,916			3,706,174

	(Loss)/income from continuing operations before income taxes			-886,227			457,113				182,170			1,404,154			1,157,210

	Income tax expense			2,750			2,750				8,376			16,754			30,630

	Net (loss)/income from continuing operations		$	-888,977		$	454,363			$	173,794		$	1,387,400		$	1,126,580

	Discontinued operations:
	Net income from discontinued operations net of income tax expense/(benefit) of $0, $0, $0 and $3,182			4,975			4,975				254,976			1,793			266,719
	Net income from discontinued operations			4,975			4,975				254,976			1,793			266,719

	Net (loss)/income		$	-884,002		$	459,338			$	428,770		$	1,389,193		$	1,393,299

	Net (loss)/income per share from continuing operations - Basic		$	-0.12		$	0.06			$	0.02		$	0.19		$	0.15

	Net income per share from discontinued operations - Basic			0			0				0.04			0			0.04

	Net (loss)/income per share - Basic		$	-0.12		$	0.06			$	0.06		$	0.19		$	0.19

	Net (loss)/income per share from continuing operations - Diluted		$	-0.12		$	0.06			$	0.02		$	0.18		$	0.15

	Net income per share from discontinued operations - Diluted			0			0				0.03			0			0.04

	Net (loss)/income per share - Diluted		$	-0.12		$	0.06			$	0.05		$	0.18		$	0.19

	A Includes the reversal of $439,508 of previously accrued and unpaid contractual minimum gross profit requirement pursuant to a signed Settlement Agreement (see note 8)


			FISCAL 2013
			Q1			Q2			Q3			Q4					YEAR
	Net sales		$	4,570,525		$	3,474,231		$	3,023,487		$	3,758,983				$	14,827,226
	Cost of goods sold			1,843,899			1,626,965			1,482,329			2,474,054		B			7,427,247
	Gross profit			2,726,626			1,847,266			1,541,158			1,284,929					7,399,979

	Operating expenses:
	Selling expenses			1,458,564			1,545,585			1,764,718			2,007,337					6,776,204
	General and administrative expenses			1,042,332			1,092,726			1,155,613			1,155,818					4,446,489
	Research and development expenses			397,131			366,257			379,901			352,769					1,496,058
	Total operating expenses			2,898,027			3,004,568			3,300,232			3,515,924					12,718,751
	Loss from operations			-171,401			-1,157,302			-1,759,074			-2,230,995					-5,318,772

	Other income/(expense):
	Interest income			13			25			18			19					75
Interest expense			-			-			-			-7					-7
Royalty income and license fees			222,679			522,385			1,025,153			741,438					2,511,655
Royalty(expense)/recovery			-3,698			-1,415			-182			-8,066					-13,361
Other			-7,577			-18,608			-25,378			-49,970					-101,533
Total other income			211,417			502,387			999,611			683,414					2,396,829

Income/(loss) from continuing operations before income taxes			40,016			-654,915			-759,463			-1,547,581					-2,921,943

Income tax expense/(benefit)			1,500			2,329			-59,126			-19,899					-75,196

Net income/(loss) from continuing operations		$	38,516		$	-657,244		$	-700,337		$	-1,527,682				$	-2,846,747

Discontinued operations:
Net income/(loss) from discontinued operations net of income tax expense/(benefit) of $0, $0, $82,968 and $(3,301)			6,318			3,475			172,007			-6,018					175,782
Net income/(loss) from discontinued operations			6,318			3,475			172,007			-6,018					175,782

Net income/(loss)		$	44,834		$	-653,769		$	-528,330		$	-1,533,700				$	-2,670,965

Net income/(loss) per share from continuing operations - Basic		$	0.01		$	-0.09		$	-0.1		$	-0.22				$	-0.4

Net income/(loss) per share from discontinued operations - Basic			0			0			0.02			0					0.02

Net income/(loss) per share - Basic		$	0.01		$	-0.09		$	-0.08		$	-0.22				$	-0.38

Net income/(loss) per share from continuing operations - Diluted		$	0.01		$	-0.09		$	-0.1		$	-0.22				$	-0.4

Net income/(loss) per share from discontinued operations - Diluted			0			0			0.02			0					0.02

Net income/(loss) per share - Diluted		$	0.01		$	-0.09		$	-0.08		$	-0.22				$	-0.38

B Includes additional inventory reserves of $835,000 as described in Note 1.

Valuation_and_Qualifying_Accou

Valuation and Qualifying Accounts

12 Months Ended

Jun. 30, 2014

Valuation and Qualifying Accounts [Abstract]

Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]

Schedule II

Column C

Column B

Additions

Column E

Balance at

charged

Balance at

Column A

beginning

to cost and

Column D

end of

Description

of period

expenses

(Deductions)

period

Allowance for doubtful accounts:

Year ended June 30:

2014

214,641

-39,811

-37,962

(A)

136,868

2013

155,739

60,000

-1,098

(A)

214,641

(A) Reduction in allowance for doubtful accounts due to write off of certain accounts receivable balances.

Basis_of_Presentation_Organiza1

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Policies)

12 Months Ended

Jun. 30, 2014

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

The consolidated financial statements of MISONIX, INC. (“Misonix” or the “Company”) include the accounts of Misonix and its 100% owned subsidiaries, Fibra-Sonics (NY) Inc. and Hearing Innovations, Inc. All significant intercompany balances and transactions have been eliminated.

Discontinued Operations, Policy [Policy Text Block]

Discontinued Operations

For the years ended

June 30,

2014

2013

Revenues

19,901

Income from discontinued operations, before tax

19,901

5,449

Gain on sale of discontinued operations

250,000

Income tax expense

-3,182

-79,667

Net income from discontinued operations, net of tax

266,719

175,782

Laboratory and Forensic Safety Products Business

On October 19, 2011, Misonix sold its Laboratory Products business, which comprised substantially all of the Laboratory and Scientific Products segment, to Mystaire, Inc. (“Mystaire”) for $1.5 million in cash plus a potential additional payment of up to an aggregate $500,000 based upon 30% of net sales in excess of $2.0 million for each of the three years following the closing (the “earn-out”). The Laboratory and Forensic Safety Products business manufactured and marketed ductless fume, laminar airflow and polymerase chain reaction workstations both domestically and internationally. The earn-out will not be factored into the gain on sale until it is earned by Misonix. As of June 30, 2014 there has been no earn-out recorded.

High Intensity Focused Ultrasound Technology

In consideration for the May 2010 sale of its rights to the high intensity focused ultrasound technology to USHIFU LLC (“USHIFU”), Misonix will receive up to approximately $5.8 million, paid out of an earn-out of 7% of gross revenues received by USHIFU related to the business being sold up to the time the Company has received the first $3 million and thereafter 5% of the gross revenues up to $5.8 million. Commencing 90 days after each December 31st and beginning December 31, 2011 the payments will be the greater of (a) $250,000 or (b) 7% of gross revenues received up to the time the Company has received the first $3 million and thereafter 5% of gross revenues up to the $5.8 million. Cumulative payments through June 30, 2014 were $754,788.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.

The Company maintains cash balances at various financial institutions. At June 30, 2014, these financial institutions held cash that was approximately $6,790,522 in excess of amounts insured by the Federal Deposit Insurance Corporation and other government agencies.

Major Customers And Concentration Of Credit Risk [Policy Text Block]

Major Customers and Concentration of Credit Risk

Included in sales from continuing operations are sales to Cicel (Beijing) Science and Tech Co. Ltd. of $2,495,960 and $619,357, Covidien plc (“Covidien”) of $5,226 and $110,437 and Aesculap, Inc. (“Aesculap”) of $636,085 and $1,425,708 for the fiscal years ended June 30, 2014 and 2013, respectively. Total royalties from Covidien related to their sales of the Company’s ultrasonic cutting products, which use high frequency sound waves to coagulate and divide tissue for both open and laparoscopic surgery, were $3,619,000 and $2,369,000 during the fiscal years ended June 30, 2014 and 2013, respectively. Accounts receivable from Covidien were approximately $892,000 and $718,000, which included $892,000 and $711,000 of royalty income receivable at June 30, 2014 and 2013, respectively. Accounts receivable from Aesculap were approximately $121,000 and $324,000 and from Cicel were approximately $606,000 and $179,000 at June 30, 2014 and 2013, respectively. At June 30, 2014 and 2013, the Company’s accounts receivable with customers outside the United States were approximately $1,332,000 and $1,086,000, respectively. The Company sells its BoneScalpel, SonaStar and Sonic One Wound Cleansing and Debridement System through direct sales persons and agents in the United States and through distributors outside the United States.

Receivables, Policy [Policy Text Block]

Accounts Receivable

Accounts receivable, principally trade, are generally due within 30 to 90 days and are stated at amounts due from customers, net of an allowance for doubtful accounts. The Company performs ongoing credit evaluations and adjusts credit limits based upon payment history and the customer's current credit worthiness, as determined by a review of their current credit information. The Company continuously monitors aging reports, collections and payments from customers and maintains a provision for estimated credit losses based upon historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within expectations and the provisions established, the Company cannot guarantee that the same credit loss rates will be experienced in the future. The Company writes off accounts receivable when they become uncollectible.

Inventory, Policy [Policy Text Block]

Inventories

Inventories are stated at the lower of cost (first-in, first-out) or market and consist of raw materials, work-in process and finished goods and include purchased materials, direct labor and manufacturing overhead. Management evaluates the need to record adjustments to write down inventory to the lower of cost or market on a quarterly basis. The Company’s policy is to assess the valuation of all inventories, including raw materials, work-in-process and finished goods and it writes down its inventory for estimated obsolescence based upon the age of inventory and assumptions about future demand and usage. During the year ended June 30, 2013 the Company also established inventory reserves aggregating approximately $835,000 resulting from terminating an agreement for products not meeting specifications for which recovery from the supplier is not expected. Inventory items used for demonstration purposes, rentals or on consignment are classified as property, plant and equipment.

Property, Plant and Equipment, Policy [Policy Text Block]

Property, Plant and Equipment

Property, plant and equipment are recorded at cost. Minor replacements and maintenance and repair expenses are charged to expense as incurred. Depreciation of property and equipment is provided using the straight-line method over estimated useful lives ranging from 3 to 5 years. Leasehold improvements are amortized over the life of the lease or the useful life of the related asset, whichever is shorter. The Company's policy is to periodically evaluate the appropriateness of the lives assigned to property, plant and equipment and make adjustments if necessary. Inventory items included in property, plant and equipment are depreciated using the straight line method over estimated useful lives of 3 to 5 years.

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

The Company records revenue upon shipment for products shipped F.O.B. shipping point. Products shipped F.O.B. destination points are recorded as revenue when received at the point of destination. Shipments under agreements with distributors are not subject to return, and payment for these shipments is not contingent on sales by the distributor. Accordingly, the Company recognizes revenue on shipments to distributors in the same manner as with other customers. Fees from exclusive license agreements are recognized ratably over the terms of the respective agreements. Service contracts and royalty income are recognized when earned.

The Company presents taxes collected from customers and remitted to governmental authorities in the consolidated statements of operations on a net basis.

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Long-Lived Assets

The carrying values of intangible and other long-lived assets, excluding goodwill, are periodically reviewed to determine if any impairment indicators are present. If it is determined that such indicators are present and the review indicates that the assets will not be fully recoverable, based on undiscounted estimated cash flows over the remaining amortization and depreciation period, their carrying values are reduced to estimated fair value. Impairment indicators include, among other conditions, cash flow deficits, an historic or anticipated decline in revenue or operating profit, adverse legal or regulatory developments, accumulation of costs significantly in excess of amounts originally expected to acquire the asset and a material decrease in the fair value of some or all of the assets. Assets are grouped at the lowest levels for which there are identifiable cash flows that are largely independent of the cash flows generated by other asset groups. No such impairment was deemed to exist in fiscal 2014 or 2013.

Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]

Goodwill

Goodwill is not amortized. We review goodwill for impairment annually and whenever events or changes indicate that the carrying value of an asset may not be recoverable. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of significant assets or products. Application of these impairment tests requires significant judgments, including estimation of cash flows, which is dependent on internal forecasts, estimation of the long term rate of growth for the Company’s business, the useful lives over which cash flows will occur and determination of the Company’s weighted average cost of capital. We primarily utilize a discontinued cashflow model in determining the fair value which consists of Level 3 inputs. Changes in the projected cash flows and discount rate estimates and assumptions underlying the valuation of goodwill could materially affect the determination of fair value at acquisition or during subsequent periods when tested for impairment. The Company completed its annual goodwill impairment tests for fiscal 2014 and 2013 as of June 30th each year. No impairment of goodwill was deemed to exist in fiscal 2014 or 2013.

Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]

Intangible and Other Assets

The cost of acquiring or processing patents is capitalized at cost. This amount is being amortized using the straight-line method over the estimated useful lives of the underlying assets, which is approximately 17 years. Net patents reported in intangible and other assets totaled $611,355 and $568,823 at June 30, 2014 and 2013, respectively. Accumulated amortization totaled $641,469 and $554,923 at June 30, 2014 and 2013, respectively. Amortization expense for the years ended June 30, 2014 and 2013 was approximately $83,000 and $75,000, respectively.

Net customer relationships, which are being amortized on a straight-line basis over a five year period, reported in intangible and other assets totaled $200,000 and $360,000 at June 30, 2014 and 2013, respectively. Accumulated amortization amounted to $600,000 and $440,000 at June 30, 2014 and 2013, respectively. Amortization expenses for the years ended June 30, 2014 and 2013 was $160,000 in each year.

The following is a schedule of estimated future amortization expense as of June 30, 2014:

Customer

Patents

Relationships

2015

85,931

160,000

2016

80,415

40,000

2017

78,231

2018

74,917

2019

68,333

Thereafter

223,528

611,355

200,000

Income Tax, Policy [Policy Text Block]

Income Taxes

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those periods in which temporary differences become deductible. Should management determine that it is more likely than not that some portion of the deferred tax asset will not be realized, a valuation allowance against the deferred tax asset would be established in the period such determination was made.

The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements from such position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. The Company classifies income tax related interest and penalties as a component of income tax expense.

Earnings Per Share, Policy [Policy Text Block]

Income (Loss) Per Share

Basic income (loss) per common share ("Basic EPS") is computed by dividing income (loss) by the weighted average number of common shares outstanding using the treasury stock method. Diluted income (loss) per common share ("Diluted EPS") is computed by dividing income (loss) by the weighted average number of common shares and the dilutive common share equivalents and convertible securities then outstanding.

The number of weighted average common shares used in the calculation of basic EPS and diluted EPS were as follows:

For the twelve months ended

For the three months ended

June 30,

2014

2013

2014

2013

Basic shares

7,232,004

7,050,423

7,301,157

7,115,557

Dilutive effect of stock options

235,588

383,685

Diluted shares

7,467,592

7,050,423

7,684,842

7,115,557

Excluded from the calculation of Diluted EPS are options to purchase 96,750 and 312,630 shares of common stock for the three and twelve months ended June 30, 2014, respectively. The excluded shares are any shares in which the average stock price for the quarter or year-to-date is less than the exercise price of the outstanding options in the period in which the Company has net income.

Diluted EPS for the three and twelve months ended June 30, 2013 presented is the same as Basic EPS, as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. For this reason, excluded from the calculations of Diluted EPS for the three and twelve months ended June 30, 2013 are outstanding options to purchase 1,729,991 shares.

Comprehensive Income, Policy [Policy Text Block]

Comprehensive Income/(Loss)

Total comprehensive income/(loss) was $1,393,299 for the fiscal year ended June 30, 2014 and ($2,670,965) for the fiscal year ended June 30, 2013.

Research and Development Expense, Policy [Policy Text Block]

Research and Development

All research and development expenses are expensed as incurred and are included in operating expenses.

Advertising Costs, Policy [Policy Text Block]

Advertising Expense

The cost of advertising is expensed in the period the advertising first takes place. The Company incurred approximately $100,000 and $141,000 in advertising costs during the fiscal years ended June 30, 2014 and 2013, respectively.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and judgments that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are used for but not limited to, establishing the allowance for doubtful accounts, valuation of inventory, depreciation, asset impairment evaluations and establishing deferred tax assets and stock-based compensation. Actual results could differ from those estimates.

Shipping and Handling Cost, Policy [Policy Text Block]

Shipping and Handling

Shipping and handling fees for the fiscal years ended June 30, 2014 and 2013 were approximately $75,000 and $47,000, respectively, and are reported as a component of net sales. Shipping and handling costs for the fiscal years ended June 30, 2014 and 2013 were approximately $85,000 and $101,000, respectively, and are reported as a component of selling expenses.

Compensation Related Costs, Policy [Policy Text Block]

Stock-Based Compensation

The Company measures compensation cost for all share based payments at fair value and recognizes the cost over the vesting period. The Company utilizes the straight line amortization method to recognize the expense associated with the awards with graded vesting terms.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-08, “Presentation of Financial Statements (Topic 205)” and “Property, Plant and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity.” The amendments in the ASU change the criteria for reporting discontinued operations while enhancing related disclosures. The amendments in the ASU are effective in the first quarter of 2015. The Company is currently evaluating the impact of the pending adoption of ASU 2014 – 08 on its consolidated financial statements.

In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)." The new revenue recognition standard provides a five-step analysis to determine when and how revenue is recognized. The standard requires that a company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective for annual periods beginning after December 15, 2016 and will be applied retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is currently evaluating the impact of the pending adoption of ASU 2014-09 on its consolidated financial statements.

Basis_of_Presentation_Organiza2

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	'
	The following is an analysis of net sales from continuing operations by geographic region:

		For the years ended June 30,
		2014		2013
	United States	$	8,185,468	$	7,649,041
	Australia		120,118		358,509
	Europe		2,387,376		3,062,307
	Asia		3,572,056		1,619,255
	Canada and Mexico		779,833		516,088
	South America		1,165,124		735,060
	South Africa		378,287		489,756
	Middle East		472,173		397,210
		$	17,060,435	$	14,827,226

Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	'
		For the years ended
		June 30,
		2014		2013
	Revenues	$	19,901	$	19,901
	Income from discontinued operations, before tax	$	19,901	$	5,449
	Gain on sale of discontinued operations		250,000		250,000
	Income tax expense		-3,182		-79,667
	Net income from discontinued operations, net of tax	$	266,719	$	175,782

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	The following is a schedule of estimated future amortization expense as of June 30, 2014:

				Customer
		Patents		Relationships
	2015	$	85,931	$	160,000
	2016		80,415		40,000
	2017		78,231		-
	2018		74,917		-
	2019		68,333		-
	Thereafter		223,528		-
		$	611,355	$	200,000

Schedule of Weighted Average Number of Shares [Table Text Block]	'
	The number of weighted average common shares used in the calculation of basic EPS and diluted EPS were as follows:

		For the twelve months ended				For the three months ended
		June 30,				June 30,
		2014		2013		2014		2013
	Basic shares		7,232,004		7,050,423		7,301,157		7,115,557
	Dilutive effect of stock options		235,588		-		383,685		-
	Diluted shares		7,467,592		7,050,423		7,684,842		7,115,557

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	12 Months Ended
Fair Value of Financial Instruments (Tables)	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Carrying Values and Estimated Fair Values of Financial Instruments [Table Text Block]	'
	The following is a summary of the carrying amounts and estimated fair values of our financial instruments:

		June 30, 2014				June 30, 2013
		Carrying		Fair		Carrying		Fair
		Amount		Value		Amount		Value
	Cash and cash equivalents	$	7,039,938	$	7,039,938	$	5,806,437	$	5,806,437
	Trade accounts receivable		3,759,152		3,759,152		2,974,641		2,974,641
	Trade accounts payable		1,650,323		1,650,323		2,208,999		2,208,999

Inventories_Tables

Inventories (Tables)	12 Months Ended
Inventories (Tables)	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
	Inventories are summarized as follows:

		June 30,		June 30,
		2014		2013
	Raw material	$	1,820,046	$	2,641,982
	Work-in-process		410,827		394,629
	Finished goods		3,337,568		2,358,943
			5,568,441		5,395,554
	Less valuation reserve		1,351,091		1,361,077
		$	4,217,350	$	4,034,477

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	12 Months Ended
Property, Plant and Equipment (Tables)	Jun. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property, plant and equipment consist of the following:

		June 30,		June 30,
		2014		2013
	Machinery and equipment	$	1,887,309	$	1,861,167
	Furniture and fixtures		1,234,104		1,185,660
	Automobiles		22,328		22,328
	Leasehold improvements		445,879		443,233
	Demonstration and consignment inventory		2,770,241		1,919,490
			6,359,861		5,431,878
	Less: accumulated depreciation and amortization		-4,842,009		-4,105,292
		$	1,517,852	$	1,326,586

Accrued_Expenses_and_Other_Cur1

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
Accrued Expenses and Other Current Liabilities (Tables)	Jun. 30, 2014
Payables and Accruals [Abstract]	'
Schedule of Accrued Expenses and Other Current Liabilities [Table Text Block]	'
	The following summarizes accrued expenses and other current liabilities:

		June 30,		June 30,
		2014		2013
	Accrued payroll and vacation	$	460,341	$	456,095
	Accrued bonuses		250,000		225,000
	Accrued commissions		340,462		200,678
	Accrued professional and legal fees		85,832		70,450
	Deferred income		102,453		146,038
	Other		218,162		178,702
		$	1,457,250	$	1,276,963

Leases_Tables

Leases (Tables)	12 Months Ended
Leases (Tables)	Jun. 30, 2014
Leases [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	The following is a schedule of future minimum lease payments, by year and in the aggregate, under operating leases with initial or remaining terms of one year or more at June 30, 2014:

		Operating
		Leases
	2015	$	332,017
	2016		33,606
	2017		28,032
	2018		7,540
	Total minimum lease payments	$	401,195

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
Stock-Based Compensation (Tables)	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'

	The weighted average fair value at date of grant for options granted during the fiscal years ended June 30, 2014 and 2013 was $3.95 and $3.04 per share, respectively. The fair value of options at date of grant was estimated using the Black-Scholes option-pricing model utilizing the following assumptions:

		2014			2013
	Risk-free interest rates		3	%		2.5	%
	Expected option life in years		6.5			6.5
	Expected stock price volatility		76.09	%		75.15	%
	Expected dividend yield		0	%		0	%

Schedule of Share-based Compensation, Activity [Table Text Block]	'
	The following table summarizes information about stock option activity during 2014 and 2013:

		Options
								Weighted
								Average
					Weighted			Remaining
		Number			Average			Contractual		Aggregate
		of			Exercise			Life		Intrinsic
		Shares			Price			Years		Value
	Outstanding as of June 30, 2013		1,729,991		$	3.65
	Granted		324,000			4.94
	Exercised		-178,212			2.72				$	341,479
	Forfeited		-50,250			4.31
	Expired		-162,200			4.67
	Outstanding as of June 30, 2014		1,663,329		$	3.88			5.2	$	4,879,106
	Vested and exercisable at June 30, 2014		967,056		$	3.81			4.3	$	2,937,802

	Outstanding as of June 30, 2012		1,820,930		$	3.6
	Granted		357,500			3.83
	Exercised		-150,964			2.45				$	86,972
	Forfeited		-95,775			2.41
	Expired		-201,700			5.1
	Outstanding as of June 30, 2013		1,729,991		$	3.65			5.4	$	2,937,132
	Vested and exercisable at June 30, 2013		1,104,817		$	3.97			3.6	$	1,554,007

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table summarizes information about stock options outstanding at June 30, 2014:

		Options Outstanding								Options Exercisable
					Weighted
					Average			Weighted				Weighted
	Range of				Contractual			Average				Average
	Exercise				Life			Exercise				Exercise
	Prices	Number			(Yrs.)			Price		Number		Price
	$0.85-2.96		850,899			6.2		$	2.38		533,601	$	2.27
	$3.45-4.68		299,800			6.2		$	4.51		56,800	$	3.76
	$5.18-8.00		512,630			3		$	6.01		376,655	$	6
			1,663,329			5.2		$	3.88		967,056	$	3.81

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	12 Months Ended
Related Party Transactions (Tables)	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Schedule of Related Party Transactions [Table Text Block]	'
	Set forth below is a table showing the Company’s net sales and accounts receivable for the fiscal years ended June 30, 2014 and June 30, 2013 with these distributors:

	For the years ended June 30,

	Applied Bio Surgical	2014		2013

	Sales	$	378,287	$	489,592
	Accounts receivable		147,585		130,123

	MD Solutions	2014		2013
	Australasia PTY Ltd.	2014		2013

	Sales	$	120,118	$	335,274
	Accounts receivable		1,785		18,700

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
	The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities are presented below:

		June 30,
		2014		2013
	Deferred tax liabilities:
	Depreciation and amortization	$	-358,421	$	-299,896
	Total deferred tax liabilities		-358,421		-299,896

	Deferred tax assets:
	Bad debt reserves		47,227		56,842
	Accruals and allowances		13,512		13,504
	Inventory valuation		612,420		611,272
	License fee and other income		31,428		59,602
	Stock-based compensation		225,925		225,793
	Deferred gain - HIFU and Labcaire		196,773		203,946
	Tax credits		702,776		534,163
	Net operating loss carry forwards		4,636,476		5,235,264
	Other		24,031		22,512
	Total deferred tax assets		6,490,568		6,962,898
	Valuation allowance		6,132,147		6,663,002
	Net deferred tax asset	$	-	$	-

	Recorded as:
	Current deferred tax asset	$	-	$	-
	Non-current deferred tax liability, net		-		-
		$	-	$	-

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	'
	Significant components of the income tax expense (benefit) attributable to continuing operations are as follows:

		Year ended June 30,
		2014		2013
	Current:
	Federal	$	24,613	$	-79,667
	State		6,017		4,471
	Total current		30,630		-75,196

	Deferred:
	Federal		-		-
	State		-		-
	Total deferred		-		-
		$	30,630	$	-75,196

Federal Income Tax Note [Table Text Block]	'
	The reconciliation of income tax expense (benefit) computed at the Federal statutory tax rates to income tax expense (benefit) is as follows:

		Year ended June 30,
		2014		2013
	Tax at federal statutory rates	$	393,451	$	-993,461
	State income taxes, net of federal benefit		3,971		2,951
	Research credit		-140,044		-58,777
	Stock-based compensation		236,941		166,080
	Valuation allowance		-486,106		782,808
	Travel and entertainment		21,587		24,860
	Other		830		343
		$	30,630	$	-75,196

Quarterly_Results_unaudited_Ta

Quarterly Results (unaudited) (Tables)	12 Months Ended
Quarterly Results (unaudited) (Tables)	Jun. 30, 2014
Quarterly Financial Information Disclosure [Abstract]	'
Schedule of Quarterly Financial Information [Table Text Block]	'
			FISCAL 2014
			Q1			Q2				Q3			Q4			YEAR
	Net sales		$	3,075,584		$	4,122,059			$	4,284,645		$	5,578,147		$	17,060,435
	Cost of goods sold			1,345,330			1,229,409	A			1,431,766			1,927,362			5,933,867
	Gross profit			1,730,254			2,892,650				2,852,879			3,650,785			11,126,568

	Operating expenses:
	Selling expenses			1,828,830			1,683,699				1,913,795			1,846,402			7,272,726
	General and administrative expenses			1,221,315			1,120,926				1,176,047			1,172,767			4,691,055
	Research and development expenses			472,888			435,019				406,466			397,378			1,711,751
	Total operating expenses			3,523,033			3,239,644				3,496,308			3,416,547			13,675,532
	(Loss)/income from operations			-1,792,779			-346,994				-643,429			234,238			-2,548,964

	Other income/(expense):
	Interest income			19			19				18			13			69
	Royalty income and license fees			912,794			809,392				830,702			1,172,548			3,725,436
	Other			-6,261			-5,304				-5,121			-2,645			-19,331
	Total other income			906,552			804,107				825,599			1,169,916			3,706,174

	(Loss)/income from continuing operations before income taxes			-886,227			457,113				182,170			1,404,154			1,157,210

	Income tax expense			2,750			2,750				8,376			16,754			30,630

	Net (loss)/income from continuing operations		$	-888,977		$	454,363			$	173,794		$	1,387,400		$	1,126,580

	Discontinued operations:
	Net income from discontinued operations net of income tax expense/(benefit) of $0, $0, $0 and $3,182			4,975			4,975				254,976			1,793			266,719
	Net income from discontinued operations			4,975			4,975				254,976			1,793			266,719

	Net (loss)/income		$	-884,002		$	459,338			$	428,770		$	1,389,193		$	1,393,299

	Net (loss)/income per share from continuing operations - Basic		$	-0.12		$	0.06			$	0.02		$	0.19		$	0.15

	Net income per share from discontinued operations - Basic			0			0				0.04			0			0.04

	Net (loss)/income per share - Basic		$	-0.12		$	0.06			$	0.06		$	0.19		$	0.19

	Net (loss)/income per share from continuing operations - Diluted		$	-0.12		$	0.06			$	0.02		$	0.18		$	0.15

	Net income per share from discontinued operations - Diluted			0			0				0.03			0			0.04

	Net (loss)/income per share - Diluted		$	-0.12		$	0.06			$	0.05		$	0.18		$	0.19

	A Includes the reversal of $439,508 of previously accrued and unpaid contractual minimum gross profit requirement pursuant to a signed Settlement Agreement (see note 8)


			FISCAL 2013
			Q1			Q2			Q3			Q4					YEAR
	Net sales		$	4,570,525		$	3,474,231		$	3,023,487		$	3,758,983				$	14,827,226
	Cost of goods sold			1,843,899			1,626,965			1,482,329			2,474,054		B			7,427,247
	Gross profit			2,726,626			1,847,266			1,541,158			1,284,929					7,399,979

	Operating expenses:
	Selling expenses			1,458,564			1,545,585			1,764,718			2,007,337					6,776,204
	General and administrative expenses			1,042,332			1,092,726			1,155,613			1,155,818					4,446,489
	Research and development expenses			397,131			366,257			379,901			352,769					1,496,058
	Total operating expenses			2,898,027			3,004,568			3,300,232			3,515,924					12,718,751
	Loss from operations			-171,401			-1,157,302			-1,759,074			-2,230,995					-5,318,772

	Other income/(expense):
	Interest income			13			25			18			19					75
	Interest expense			-			-			-			-7					-7
	Royalty income and license fees			222,679			522,385			1,025,153			741,438					2,511,655
Royalty(expense)/recovery			-3,698			-1,415			-182			-8,066					-13,361
Other			-7,577			-18,608			-25,378			-49,970					-101,533
Total other income			211,417			502,387			999,611			683,414					2,396,829

Income/(loss) from continuing operations before income taxes			40,016			-654,915			-759,463			-1,547,581					-2,921,943

Income tax expense/(benefit)			1,500			2,329			-59,126			-19,899					-75,196

Net income/(loss) from continuing operations		$	38,516		$	-657,244		$	-700,337		$	-1,527,682				$	-2,846,747

Discontinued operations:
Net income/(loss) from discontinued operations net of income tax expense/(benefit) of $0, $0, $82,968 and $(3,301)			6,318			3,475			172,007			-6,018					175,782
Net income/(loss) from discontinued operations			6,318			3,475			172,007			-6,018					175,782

Net income/(loss)		$	44,834		$	-653,769		$	-528,330		$	-1,533,700				$	-2,670,965

Net income/(loss) per share from continuing operations - Basic		$	0.01		$	-0.09		$	-0.1		$	-0.22				$	-0.4

Net income/(loss) per share from discontinued operations - Basic			0			0			0.02			0					0.02

Net income/(loss) per share - Basic		$	0.01		$	-0.09		$	-0.08		$	-0.22				$	-0.38

Net income/(loss) per share from continuing operations - Diluted		$	0.01		$	-0.09		$	-0.1		$	-0.22				$	-0.4

Net income/(loss) per share from discontinued operations - Diluted			0			0			0.02			0					0.02

Net income/(loss) per share - Diluted		$	0.01		$	-0.09		$	-0.08		$	-0.22				$	-0.38

B Includes additional inventory reserves of $835,000 as described in Note 1.

Basis_of_Presentation_Organiza3

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended								12 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	$5,578,147	$4,284,645	$4,122,059	$3,075,584	$3,758,983	$3,023,487	$3,474,231	$4,570,525	$17,060,435	$14,827,226
UNITED STATES	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	8,185,468	7,649,041
AUSTRALIA	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	120,118	358,509
SOUTH AFRICA	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	378,287	489,756
EUROPE	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	2,387,376	3,062,307
ASIA	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	3,572,056	1,619,255
CANADA AND MEXICO	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	779,833	516,088
SOUTH AMERICA	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	1,165,124	735,060
MIDDLE EAST	'	'	'	'	'	'	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'	'	'	'	'	'	'
Net sales	'	'	'	'	'	'	'	'	$472,173	$397,210

Basis_of_Presentation_Organiza4

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Details 1) (USD $)	3 Months Ended								12 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	$19,901	$19,901
Income from discontinued operations, before tax	'	'	'	'	'	'	'	'	19,901	5,449
Gain on sale of discontinued operations	'	'	'	'	'	'	'	'	250,000	250,000
Income tax expense	-3,182	0	0	0	3,301	-82,968	0	0	-3,182	-79,667
Net income from discontinued operations, net of tax	$1,793	$254,976	$4,975	$4,975	($6,018)	$172,007	$3,475	$6,318	$266,719	$175,782

Basis_of_Presentation_Organiza5

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Details 2) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
2015	$85,931	'
2016	80,415	'
2017	78,231	'
2018	74,917	'
2019	68,333	'
Thereafter	223,528	'
Finite-Lived Intangible Assets, Future Amortization Expense	611,355	568,823
Customer Relationships [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
2015	160,000	'
2016	40,000	'
2017	0	'
2018	0	'
2019	0	'
Thereafter	0	'
Finite-Lived Intangible Assets, Future Amortization Expense	$200,000	$360,000

Basis_of_Presentation_Organiza6

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Details 3)	3 Months Ended		12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Earnings Per Share, Diluted, Other Disclosures [Abstract]	'	'	'	'
Basic shares	7,301,157	7,115,557	7,232,004	7,050,423
Dilutive effect of stock options	383,685	0	235,588	0
Diluted shares	7,684,842	7,115,557	7,467,592	7,050,423

Basis_of_Presentation_Organiza7

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Details Textual) (USD $)

3 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Oct. 19, 2011

31-May-10

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

UNITED STATES

Minimum [Member]

Maximum [Member]

Laboratory and Forensic Safety Products Business [Member]

High Intensity Focused Ultrasound Technology [Member]

Fibra Sonics Ny Inc [Member]

Cicel Science [Member]

Tech Co. Ltd [Member]

Covidien [Member]

Aesculap, Inc [Member]

Sales [Member]

Selling Expense [Member]

Patents [Member]

Customer Relationships [Member]

Medical Devices Segment [Member]

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies [Line Items]

Equity Method Investment, Ownership Percentage

100.00%

Proceeds from Sales of Business, Affiliate and Productive Assets

$1,500,000

Sale of Business Potential Additional Payment

500,000

Sale of Business Potential Additional Payment Determination Basis

'based upon 30% of net sales in excess of $2.0 million for each of the three years following the closing (the earn-out).

Proceeds from Sales of Intangible Assets

5,800,000

Sale of Intangible Assets Percentage of Gross Revenue Received as Earn Out Up to First Benchmark

7.00%

Proceeds from Sale of Intangible Assets First Benchmark

3,000,000

Sale of Intangible Assets Percentage of Gross Revenue Received as Earn Out Up to Second Benchmark

5.00%

Proceeds from Sale of Intangible Assets Second Benchmark

5,800,000

Payment Sale Of Intangible Assets Description

'Commencing 90 days after each December 31st and beginning December 31, 2011 the payments will be the greater of (a) $250,000 or (b) 7% of gross revenues received up to the time the Company has received the first $3 million and thereafter 5% of gross revenues up to the $5.8 million.

Payment Sale Of Intangible Assets

754,788

Cash, Uninsured Amount

6,790,522

Sales Revenue, Goods, Net, Total

5,578,147

4,284,645

4,122,059

3,075,584

3,758,983

3,023,487

3,474,231

4,570,525

17,060,435

14,827,226

2,495,960

619,357

5,226

110,437

636,085

1,425,708

Royalty Expense

8,066

182

1,415

3,698

13,361

3,619,000

2,369,000

Accounts Receivable, Net, Current, Total

3,759,152

2,974,641

3,759,152

2,974,641

1,332,000

1,086,000

606,000

179,000

892,000

718,000

121,000

324,000

Royalty Income, Nonoperating

1,172,548

830,702

809,392

912,794

741,438

1,025,153

522,385

222,679

3,725,436

2,511,655

892,000

711,000

Additional Inventory Reserves

835,000

Property, Plant and Equipment, Estimated Useful Lives

'3 years

'5 years

Finite-Lived Intangible Asset, Useful Life

'17 years

Finite-Lived Intangible Assets, Net, Total

611,355

568,823

200,000

360,000

Finite-Lived Intangible Assets, Accumulated Amortization

641,469

554,923

600,000

440,000

Amortization of Intangible Assets

83,000

75,000

160,000

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount

96,750

1,729,991

312,630

1,729,991

Comprehensive Income (Loss), Net of Tax, Attributable to Parent

1,393,299

-2,670,965

Advertising Expense

100,000

141,000

Shipping, Handling and Transportation Costs

$75,000

$47,000

$85,000

$101,000

Accounts receivable due number of days

'30 days

'90 days

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'
Cash and cash equivalents, Carrying Amount	$7,039,938	$5,806,437	$6,273,015
Trade accounts receivable, Carrying Amount	3,759,152	2,974,641	'
Trade accounts payable, Carrying Amount	1,650,323	2,208,999	'
Cash and cash equivalents, Fair Value	7,039,938	5,806,437	'
Trade accounts receivable, Fair Value	3,759,152	2,974,641	'
Trade accounts payable, Fair Value	$1,650,323	$2,208,999	'

Inventories_Details

Inventories (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Inventory [Line Items]	'	'
Raw material	$1,820,046	$2,641,982
Work-in-process	410,827	394,629
Finished goods	3,337,568	2,358,943
Inventory, Gross	5,568,441	5,395,554
Less valuation reserve	1,351,091	1,361,077
Inventory, Net, Total	$4,217,350	$4,034,477

Property_Plant_and_Equipment_D

Property, Plant and Equipment (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Property, Plant and Equipment [Line Items]	'	'
Machinery and equipment	$1,887,309	$1,861,167
Furniture and fixtures	1,234,104	1,185,660
Automobiles	22,328	22,328
Leasehold improvements	445,879	443,233
Demonstration and consignment inventory	2,770,241	1,919,490
Property, Plant and Equipment, Gross	6,359,861	5,431,878
Less: accumulated depreciation and amortization	-4,842,009	-4,105,292
Property, Plant and Equipment, Net	$1,517,852	$1,326,586

Property_Plant_and_Equipment_D1

Property, Plant and Equipment (Details Textual) (USD $)	12 Months Ended
Property, Plant and Equipment (Details Textual) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Property, Plant and Equipment [Line Items]	'	'
Depreciation, Depletion and Amortization	$732,000	$550,000

Accrued_Expenses_and_Other_Cur2

Accrued Expenses and Other Current Liabilities (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Accrued Liabilities, Current [Abstract]	'	'
Accrued payroll and vacation	$460,341	$456,095
Accrued bonuses	250,000	225,000
Accrued commissions	340,462	200,678
Accrued professional and legal fees	85,832	70,450
Deferred income	102,453	146,038
Other	218,162	178,702
Accrued Expenses and Other Current Liabilities	$1,457,250	$1,276,963

Leases_Details

Leases (Details) (USD $)	Jun. 30, 2014
Operating Leased Assets [Line Items]	'
Operating Leases, 2015	$332,017
Operating Leases, 2016	33,606
Operating Leases, 2017	28,032
Operating Leases, 2018	7,540
Operating Leases, Total minimum lease payments	$401,195

Leases_Details_Textual

Leases (Details Textual) (USD $)	12 Months Ended
Leases (Details Textual) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Operating Leased Assets [Line Items]	'	'
Operating Leases, Rent Expense, Net	$392,000	$387,000
Sale Leaseback Transaction, Monthly Rental Payments	$23,000	'
Operating Lease Expiration Period	'fiscal 2018	'

StockBased_Compensation_Plans_

Stock-Based Compensation Plans (Details)	12 Months Ended
Stock-Based Compensation Plans (Details)	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Risk-free interest rate	3.00%	2.50%
Expected option life in years	'6 years 6 months	'6 years 6 months
Expected stock price volatility	76.09%	75.15%
Expected dividend yield	0.00%	0.00%

StockBased_Compensation_Plans_1

Stock-Based Compensation Plans (Details 1) (USD $)	12 Months Ended
Stock-Based Compensation Plans (Details 1) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Number of Shares, Outstanding at beginning of period	1,729,991	'
Number of Shares, Outstanding at end of period	1,663,329	'
Weighte Average Remaining Contractual Life, Outstanding (in years)	'5 years 2 months 12 days	'
Employee Stock Option [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Number of Shares, Outstanding at beginning of period	1,729,991	1,820,930
Number of Shares, Granted	324,000	357,500
Number of Shares, Exercised	-178,212	-150,964
Number of Shares, Forfeited	-50,250	-95,775
Number of Shares, Expired	-162,200	-201,700
Number of Shares, Outstanding at end of period	1,663,329	1,729,991
Number of Shares, Vested and exercisable	967,056	1,104,817
Weighted Average Exercise Price, Outstanding at beginning of period	$3.65	$3.60
Weighted Average Exercise Price, Granted	$4.94	$3.83
Weighted Average Exercise Price, Exercised	$2.72	$2.45
Weighted Average Exercise Price, Forfeited	$4.31	$2.41
Weighted Average Exercise Price, Expired	$4.67	$5.10
Weighted Average Exercise Price, Outstanding at end of period	$3.88	$3.65
Weighted Average Exercise Price, Vested and exercisable	$3.81	$3.97
Weighte Average Remaining Contractual Life, Outstanding (in years)	'5 years 2 months 12 days	'5 years 4 months 24 days
Weighte Average Remaining Contractual Life, Vested and exercisable (in years)	'4 years 3 months 18 days	'3 years 7 months 6 days
Aggregate Intrinsic Value, Exercised (in dollars)	$341,479	$86,972
Aggregate Intrinsic Value, Outstanding (in dollars)	4,879,106	2,937,132
Aggregate Intrinsic Value, Vested and exercisable (in dollars)	$2,937,802	$1,554,007

StockBased_Compensation_Plans_2

Stock-Based Compensation Plans (Details 2) (USD $)	12 Months Ended
Stock-Based Compensation Plans (Details 2) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Number (in shares)	1,663,329	1,729,991
Options Outstanding, Weighted Average Contractual Life (in years)	'5 years 2 months 12 days	'
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$3.88	'
Options Exercisable, Number (in shares)	967,056	'
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$3.81	'
Range Of Exercise Price 0.85 - 2.96 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Number (in shares)	850,899	'
Options Outstanding, Weighted Average Contractual Life (in years)	'6 years 2 months 12 days	'
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$2.38	'
Options Exercisable, Number (in shares)	533,601	'
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$2.27	'
Range Of Exercise Price 3.45 - 4.68 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Number (in shares)	299,800	'
Options Outstanding, Weighted Average Contractual Life (in years)	'6 years 2 months 12 days	'
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$4.51	'
Options Exercisable, Number (in shares)	56,800	'
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$3.76	'
Range Of Exercise Price 5.18 - 8.00 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Number (in shares)	512,630	'
Options Outstanding, Weighted Average Contractual Life (in years)	'3 years	'
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$6.01	'
Options Exercisable, Number (in shares)	376,655	'
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$6	'

StockBased_Compensation_Plans_3

Stock-Based Compensation Plans (Details Textual) (USD $)	12 Months Ended
Stock-Based Compensation Plans (Details Textual) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award	'not to exceed 10 years	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period	324,000	357,500
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options	$1,693,000	'
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 1	'2 years 9 months 18 days	'
Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options	484,960	369,646
Common Stock, Par or Stated Value Per Share	$0.01	$0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$341,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$3.95	$3.04
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	1,663,329	1,729,991
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	564,475	854,725
Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period, Description	'The selection of participants, allotments of shares and determination of price and other conditions relating to options are determined by the Board of Directors or a committee thereof, depending on the Plan, and in accordance with Rule 4350(c) of the Corporate Governance Requirements applicable to Nasdaq-listed companies. Incentive stock options granted under the plans are exercisable for a period of up to ten years from the date of grant at an exercise price which is not less than the fair market value of the Common Stock on the date of the grant, except that the term of an incentive stock option granted under the plans to a shareholder owning more than 10% of the outstanding Common Stock may not exceed five years and its exercise price may not be less than 110% of the fair market value of the Common Stock on the date of grant. Options shall become exercisable at such time and in such installments as provided in the terms of each individual option agreement.	'
Share-based Compensation Arrangement by Share-based Payment Award, Description	'All outstanding options expire between September 2014 and December 2023 and vest over periods of up to four years.	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'4 years	'
Exercise Price Range One Point Eight Two To Eight [Member] \| Maximum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'4 years	'
Plan 1996 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	450,000	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period	138,295	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period	422,650	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	270,705	'
Plan 1996 [Member] \| Exercise Price Range Five Point One Eight To Seven Point Six Zero [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	41,000	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$5.18	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$7.60	'
Plan 1998 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	500,000	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period	76,848	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period	477,677	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	65,275	'
Plan 1998 [Member] \| Exercise Price Range Seven Point Six Zero [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	10,750	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$7.60	'
Plan 2001 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,000,000	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period	192,318	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period	837,975	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	251,261	'
Plan 2001 [Member] \| Exercise Price Range One Point Eight Two To Eight [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	220,968	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$1.82	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$8	'
Plan 2001 [Member] \| Exercise Price Range One Point Eight Two To Eight [Member] \| Minimum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'1 year	'
Plan 2005 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	500,000	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period	169,450	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period	47,750	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	47,125	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	625	'
Plan 2005 [Member] \| Exercise Price Range Zero Point Eight Five To Six Point One Eight [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	329,925	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$0.85	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$6.18	'
Plan 2009 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	500,000	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period	20,464	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period	76,525	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	67,925	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	8,600	'
Plan 2009 [Member] \| Exercise Price Range One Point Eight Two To Six Point One Eight [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	470,936	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$1.82	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$6.18	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'4 years	'
Plan 2009 [Member] \| Exercise Price Range Two Point Four One To Six Point Seven One [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	176,250	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$2.41	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$6.71	'
Plan 2012 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	500,000	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period	6,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	326,500	'
Plan 2012 [Member] \| Exercise Price Range Four Point Six eight [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$4.68	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'4 years	'
Directors Plan 1996 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,125,000	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period	853,500	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period	130,000	'
Directors Plan 1996 [Member] \| Exercise Price Range Five Point Eight Seven To Seven Point Six Zero [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	75,000	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$5.87	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$7.60	'
Directors Plan 2005 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	200,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	165,000	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period	22,500	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period	7,500	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	12,500	'
Directors Plan 2005 [Member] \| Exercise Price Range Two Point Four One To Five Point Four Two [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$2.41	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$5.42	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'3 years	'
Directors Plan 2009 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	200,000	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period	7,500	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period	11,250	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	16,250	'
Directors Plan 2009 [Member] \| Exercise Price Range Two Point Four One To Six Point Seven One [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'4 years	'
Directors Plan 2012 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	200,000	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period	173,500	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	200,000	'

Commitment_and_Contingencies_D

Commitment and Contingencies (Details Textual) (USD $)	3 Months Ended								12 Months Ended
Commitment and Contingencies (Details Textual) (USD $)	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013
Commitments and Contingencies [Line Items]	'	'	'	'	'	'	'	'	'	'
Gross Profit, Total	$3,650,785	$2,852,879	$2,892,650	$1,730,254	$1,284,929	$1,541,158	$1,847,266	$2,726,626	$11,126,568	$7,399,979
Inventory, Net, Total	4,217,350	'	'	'	4,034,477	'	'	'	4,217,350	4,034,477
Fourth Quarter 2013 [Member] \| Minimum [Member]	'	'	'	'	'	'	'	'	'	'
Commitments and Contingencies [Line Items]	'	'	'	'	'	'	'	'	'	'
Gross Profit, Total	'	'	'	'	'	'	'	'	439,508	'
Purchase Commitments [Member]	'	'	'	'	'	'	'	'	'	'
Commitments and Contingencies [Line Items]	'	'	'	'	'	'	'	'	'	'
Inventory, Net, Total	2,300,949	'	'	'	1,510,566	'	'	'	2,300,949	1,510,566
Michael A McManus [Member]	'	'	'	'	'	'	'	'	'	'
Commitments and Contingencies [Line Items]	'	'	'	'	'	'	'	'	'	'
Salaries, Wages and Officers' Compensation	'	'	'	'	'	'	'	'	$299,000	'

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	12 Months Ended
Related Party Transactions (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Applied Bio Surgical [Member]	'	'
Related Party Transaction [Line Items]	'	'
Sales	$378,287	$489,592
Accounts receivable	147,585	130,123
MD Solutions Australasia PTY Ltd [Member]	'	'
Related Party Transaction [Line Items]	'	'
Sales	120,118	335,274
Accounts receivable	$1,785	$18,700

Income_Taxes_Details

Income Taxes (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Deferred tax liabilities:	'	'
Depreciation and amortization	($358,421)	($299,896)
Total deferred tax liabilities	-358,421	-299,896
Deferred tax assets:	'	'
Bad debt reserves	47,227	56,842
Accruals and allowances	13,512	13,504
Inventory valuation	612,420	611,272
License fee and other income	31,428	59,602
Stock-based compensation	225,925	225,793
Deferred gain - HIFU and Labcaire	196,773	203,946
Tax credits	702,776	534,163
Net operating loss carry forwards	4,636,476	5,235,264
Other	24,031	22,512
Total deferred tax assets	6,490,568	6,962,898
Valuation allowance	6,132,147	6,663,002
Net deferred tax asset	0	0
Recorded as:	'	'
Current deferred tax asset	0	0
Non-current deferred tax liability, net	0	0
Deferred Tax Assets,Total	$0	$0

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	3 Months Ended								12 Months Ended
Income Taxes (Details 1) (USD $)	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013
Current:	'	'	'	'	'	'	'	'	'	'
Federal	'	'	'	'	'	'	'	'	$24,613	($79,667)
State	'	'	'	'	'	'	'	'	6,017	4,471
Total current	'	'	'	'	'	'	'	'	30,630	-75,196
Deferred:	'	'	'	'	'	'	'	'	'	'
Federal	'	'	'	'	'	'	'	'	0	0
State	'	'	'	'	'	'	'	'	0	0
Total deferred	'	'	'	'	'	'	'	'	0	0
Income tax expense (benefit),Total	$16,754	$8,376	$2,750	$2,750	($19,899)	($59,126)	$2,329	$1,500	$30,630	($75,196)

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	3 Months Ended								12 Months Ended
Income Taxes (Details 2) (USD $)	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013
Tax at federal statutory rates	'	'	'	'	'	'	'	'	$393,451	($993,461)
State income taxes, net of federal benefit	'	'	'	'	'	'	'	'	3,971	2,951
Research credit	'	'	'	'	'	'	'	'	-140,044	-58,777
Stock-based compensation	'	'	'	'	'	'	'	'	236,941	166,080
Valuation allowance	'	'	'	'	'	'	'	'	-486,106	782,808
Travel and entertainment	'	'	'	'	'	'	'	'	21,587	24,860
Other	'	'	'	'	'	'	'	'	830	343
Income tax expense (benefit),Total	$16,754	$8,376	$2,750	$2,750	($19,899)	($59,126)	$2,329	$1,500	$30,630	($75,196)

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014
Income Taxes (Details Textual) (USD $)	Jun. 30, 2014	Minimum [Member]	Maximum [Member]	U S Federal [Member]
Income Taxes [Line Items]	'	'	'	'
Operating Loss Carryforwards	$3,900,000	'	'	$11,700,000
Deferred Tax Assets, Tax Credit Carryforwards, Research	596,000	'	'	'
Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax	$107,000	'	'	'
Expiration Date Of Tax Credit Carryforward	'	'2026	'2033	'

Licensing_Agreements_for_Medic1

Licensing Agreements for Medical Technology (Details Textual) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Proceeds from License Fees Received	$475,000	'
Proceeds from Royalties Received	$3,619,000	$2,369,000
License Agreement Expiration Period	'2016-10	'

Employee_Profit_Sharing_Plan_D

Employee Profit Sharing Plan (Details Textual) (USD $)	12 Months Ended
Employee Profit Sharing Plan (Details Textual) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Employee Benefits And Share Based Compensation Age Limit For Discretion	'50 years	'
Maximum [Member]	'	'
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount	$23,000	'
Minimum [Member]	'	'
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount	17,500	'
Supplemental Employee Retirement Plan, Defined Benefit [Member]	'	'
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	10.00%	'
Defined Contribution Plan Employers Matching Contribution Amount	$38,320	$38,510

Quarterly_Results_unaudited_De

Quarterly Results (unaudited) (Details) (USD $)	3 Months Ended										12 Months Ended
Quarterly Results (unaudited) (Details) (USD $)	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013		Sep. 30, 2013	Jun. 30, 2013		Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013
Net sales	$5,578,147	$4,284,645	$4,122,059		$3,075,584	$3,758,983		$3,023,487	$3,474,231	$4,570,525	$17,060,435	$14,827,226
Cost of goods sold	1,927,362	1,431,766	1,229,409	[1]	1,345,330	2,474,054	[2]	1,482,329	1,626,965	1,843,899	5,933,867	7,427,247
Gross profit	3,650,785	2,852,879	2,892,650		1,730,254	1,284,929		1,541,158	1,847,266	2,726,626	11,126,568	7,399,979
Operating expenses:	'	'	'		'	'		'	'	'	'	'
Selling expenses	1,846,402	1,913,795	1,683,699		1,828,830	2,007,337		1,764,718	1,545,585	1,458,564	7,272,726	6,776,204
General and administrative expenses	1,172,767	1,176,047	1,120,926		1,221,315	1,155,818		1,155,613	1,092,726	1,042,332	4,691,055	4,446,489
Research and development expenses	397,378	406,466	435,019		472,888	352,769		379,901	366,257	397,131	1,711,751	1,496,058
Total operating expenses	3,416,547	3,496,308	3,239,644		3,523,033	3,515,924		3,300,232	3,004,568	2,898,027	13,675,532	12,718,751
Loss from operations	234,238	-643,429	-346,994		-1,792,779	-2,230,995		-1,759,074	-1,157,302	-171,401	-2,548,964	-5,318,772
Other income/(expense):	'	'	'		'	'		'	'	'	'	'
Interest income	13	18	19		19	19		18	25	13	69	75
Interest expense	'	'	'		'	-7		0	0	0	0	-7
Royalty income and license fees	1,172,548	830,702	809,392		912,794	741,438		1,025,153	522,385	222,679	3,725,436	2,511,655
Royalty(expense)/recovery	'	'	'		'	-8,066		-182	-1,415	-3,698	0	-13,361
Other	-2,645	-5,121	-5,304		-6,261	-49,970		-25,378	-18,608	-7,577	-19,331	-101,533
Total other income	1,169,916	825,599	804,107		906,552	683,414		999,611	502,387	211,417	3,706,174	2,396,829
Income/(loss) from continuing operations before income taxes	1,404,154	182,170	457,113		-886,227	-1,547,581		-759,463	-654,915	40,016	1,157,210	-2,921,943
Income tax expense/(benefit)	16,754	8,376	2,750		2,750	-19,899		-59,126	2,329	1,500	30,630	-75,196
Net income/(loss) from continuing operations	1,387,400	173,794	454,363		-888,977	-1,527,682		-700,337	-657,244	38,516	1,126,580	-2,846,747
Discontinued operations:	'	'	'		'	'		'	'	'	'	'
Net income from discontinued operations net of income tax expense/(benefit)	1,793	254,976	4,975		4,975	-6,018		172,007	3,475	6,318	266,719	175,782
Net income from discontinued operations	1,793	254,976	4,975		4,975	-6,018		172,007	3,475	6,318	266,719	175,782
Net income/(loss)	$1,389,193	$428,770	$459,338		($884,002)	($1,533,700)		($528,330)	($653,769)	$44,834	$1,393,299	($2,670,965)
Net income/(loss) per share from continuing operations - Basic	$0.19	$0.02	$0.06		($0.12)	($0.22)		($0.10)	($0.09)	$0.01	$0.15	($0.40)
Net income/(loss) per share from discontinued operations - Basic	$0	$0.04	$0		$0	$0		$0.02	$0	$0	$0.04	$0.02
Net income/(loss) per share - Basic (in dollars per share)	$0.19	$0.06	$0.06		($0.12)	($0.22)		($0.08)	($0.09)	$0.01	$0.19	($0.38)
Net income/(loss) per share from continuing operations - Diluted	$0.18	$0.02	$0.06		($0.12)	($0.22)		($0.10)	($0.09)	$0.01	$0.15	($0.40)
Net income/(loss) per share from discontinued operations - Diluted	$0	$0.03	$0		$0	$0		$0.02	$0	$0	$0.04	$0.02
Net income/(loss) per share - Diluted (in dollars per share)	$0.18	$0.05	$0.06		($0.12)	($0.22)		($0.08)	($0.09)	$0.01	$0.19	($0.38)

[1]	Includes the reversal of $439,508 of previously accrued and unpaid contractual minimum gross profit requirement pursuant to a signed Settlement Agreement (see note 8)
[2]	Includes additional inventory reserves of $835,000 as described in Note 1.

Quarterly_Results_unaudited_De1

Quarterly Results (unaudited) (Details Textual) (USD $)	3 Months Ended								12 Months Ended
Quarterly Results (unaudited) (Details Textual) (USD $)	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013
Discontinued Operation, Tax Effect Of Discontinued Operation	$3,182	$0	$0	$0	($3,301)	$82,968	$0	$0	$3,182	$79,667
Additional Inventory Reserves	835,000	'	'	'	835,000	'	'	'	835,000	835,000
Gross Profit, Total	3,650,785	2,852,879	2,892,650	1,730,254	1,284,929	1,541,158	1,847,266	2,726,626	11,126,568	7,399,979
Fourth Quarter 2013 [Member] \| Minimum [Member]	'	'	'	'	'	'	'	'	'	'
Gross Profit, Total	'	'	'	'	'	'	'	'	$439,508	'

Valuation_and_Qualifying_Accou1

Valuation and Qualifying Accounts (Details) (USD $)	12 Months Ended
Valuation and Qualifying Accounts (Details) (USD $)	Jun. 30, 2014		Jun. 30, 2013
Balance at beginning of period	$214,641		$155,739
Additions charged to cost and expenses	-39,811		60,000
Deductions	-37,962	[1]	-1,098	[1]
Balance at end of period	$136,868		$214,641

[1]	Reduction in allowance for doubtful accounts due to write off of certain accounts receivable balances.